Supporting Information

for

Regioselective N-alkylation of the 1H-indazole scaffold; ring substituent and N-alkylating reagent effects on regioisomeric distribution

Ryan M. Alam and John J. Keating

Beilstein J. Org. Chem. 2021, 17, 1939–1951. doi:10.3762/bjoc.17.127

Compound synthesis, characterisation, and copies of spectral data pertaining to regioisomeric distribution (N-1:N-2) determination
Table of Contents

Experimental Note........................................................................................................... S6

Synthesis of C-3 substituted 1H-indazoles ....................................................................... S7
  1H-Indazole-3-carboxylic acid ......................................................................................... S7
  Methyl 1H-indazole-3-carboxylate (9) ........................................................................... S9
  1H-indazole (12) ............................................................................................................ S11
  3-(o-Tolyl diazenyl)-1H-indazole .................................................................................. S13
  3-tert-Butyl-1H-indazole (14) ....................................................................................... S15
  3-Phenyl-1H-indazole (15) ............................................................................................ S17
  3-Iodo-1H-indazole (16) ............................................................................................... S19
  3-Bromo-1H-indazole (17) ............................................................................................. S21
  3-Nitro-1H-indazole (19) ............................................................................................... S23
  1H-Indazole-3-carboxaldehyde (21) .............................................................................. S25
  N-Methyl-1H-indazole-3-carboxamide (23) ................................................................. S27
  (1H-Indazol-3-yl)(pyrrolidin-1-yl)methanone (24) ...................................................... S29
  1H-indazole N-alkylation .............................................................................................. S31

General Procedure (A): .................................................................................................. S31

General Procedure (B): ................................................................................................... S31

Note: Order of Elution of N-1 and N-2 Regioisomers using Wet Flash Column
  Chromatography ............................................................................................................. S32

  Methyl 1-n-pentyl-1H-indazole-3-carboxylate (10) ...................................................... S32

  Methyl 2-n-pentyl-2H-indazole-3-carboxylate (11) ...................................................... S34

  N-Alkylation of Methyl Ester 9 under Mitsunobu Conditions ....................................... S36

  1-n-Pentyl-1H-indazole (25) ......................................................................................... S37

  2-n-Pentyl-2H-indazole (26) ........................................................................................ S39

  3-Methyl-1-n-pentyl-1H-indazole (27) ......................................................................... S41

  3-Methyl-2-n-pentyl-2H-indazole (28) ......................................................................... S43

  3-tert-Butyl-1-n-pentyl-1H-indazole (29) .................................................................... S45

  3-Phenyl-1-n-pentyl-1H-indazole (31) ......................................................................... S47

  3-Phenyl-2-n-pentyl-2H-indazole (32) ......................................................................... S49

  3-Iodo-1-n-pentyl-1H-indazole (33) ............................................................................. S51

  3-Iodo-2-n-pentyl-2H-indazole (34) ............................................................................. S53

  3-Bromo-1-n-pentyl-1H-indazole (35) ......................................................................... S55

  3-Bromo-2-n-pentyl-2H-indazole (36) ......................................................................... S57
3-Chloro-1-n-pentyl-1H-indazole (37)........................................................................ S59
3-Chloro-2-n-pentyl-2H-indazole (38)........................................................................ S61
3-Nitro-1-n-pentyl-1H-indazole (39)........................................................................ S63
3-Nitro-2-n-pentyl-2H-indazole (40)........................................................................ S65
1-n-Pentyl-1H-indazole-3-carbonitrile (41)................................................................ S67
1-n-Pentyl-1H-indazole-3-carboxaldehyde (43)......................................................... S69
1-(1-n-Pentyl-1H-indazol-3-yl)ethan-1-one (45)....................................................... S71
N-Methyl-1-n-pentyl-1H-indazole-3-carboxamide (47)............................................ S73
(1-n-Pentyl-1H-indazol-3-yl)(pyrrolidin-1-yl)methanone (49)............................ S75
7-Methyl-1-n-pentyl-1H-indazole (51)................................................................. S77
7-Methyl-2-n-pentyl-2H-indazole (52)................................................................. S79
7-Bromo-1-n-pentyl-1H-indazole (53)................................................................. S81
7-Bromo-2-n-pentyl-2H-indazole (54)................................................................. S83
7-Nitro-1-n-pentyl-1H-indazole (55)................................................................. S85
7-Nitro-2-n-pentyl-2H-indazole (56)................................................................. S87
Methyl 1-n-pentyl-1H-indazole-7-carboxylate (57)............................................. S89
Methyl 2-n-pentyl-2H-indazole-7-carboxylate (58)............................................. S91
Methyl 1-n-pentyl-1H-indazole-6-carboxylate (59)............................................. S93
Methyl 2-n-pentyl-2H-indazole-6-carboxylate (60)............................................. S95
Methyl 1-n-pentyl-1H-indazole-5-carboxylate (61)............................................. S97
Methyl 2-n-pentyl-2H-indazole-5-carboxylate (62)............................................. S99
Methyl 1-n-pentyl-1H-indazole-4-carboxylate (63)............................................. S101
Methyl 2-n-pentyl-2H-indazole-4-carboxylate (64)............................................. S103
Methyl 1-benzyl-1H-indazole-3-carboxylate (69)............................................... S105
Methyl 2-benzyl-2H-indazole-3-carboxylate (70)............................................... S107
Methyl 1-(2-methylbenzyl)-1H-indazole-3-carboxylate (71)........................ S109
Methyl 2-(2-methylbenzyl)-2H-indazole-3-carboxylate (72)........................ S111
Methyl 1-(cyclohexylmethyl)-1H-indazole-3-carboxylate (73).................... S113
Methyl 2-(cyclohexylmethyl)-2H-indazole-3-carboxylate (74).................... S115
Methyl 1-(pentan-2-yl)-1H-indazole-3-carboxylate (75)................................. S117
Methyl 2-(pentan-2-yl)-2H-indazole-3-carboxylate (76)................................. S119
Methyl 1-(pentan-3-yl)-1H-indazole-3-carboxylate (77)................................. S121
Methyl 2-(pentan-3-yl)-2H-indazole-3-carboxylate (78)................................. S123

Synthesis of Tosylates.......................................................................................... S125
General Procedure (C):....................................................................................... S125
Regioisomeric distribution (N-1:N-2) determination; Crude $^1$H NMR spectra

Table 1, Entry 3

Table 1, Entry 18

Scheme 1

Table 2, Entry 1 (Conditions A)

Table 2, Entry 1 (Conditions B)

Table 2, Entry 2 (Conditions A)

Table 2, Entry 2 (Conditions B)

Table 2, Entry 3 (Conditions A)

Table 2, Entry 3 (Conditions B)

Table 2, Entry 4 (Conditions A)

Table 2, Entry 4 (Conditions B)

Table 2, Entry 5 (Conditions A)

Table 2, Entry 5 (Conditions B)

Table 2, Entry 6 (Conditions A)

Table 2, Entry 6 (Conditions B)

Table 2, Entry 7 (Conditions A)

Table 2, Entry 7 (Conditions B)

Table 2, Entry 8 (Conditions A)

Table 2, Entry 8 (Conditions B)

Table 2, Entry 9 (Conditions A)

Table 2, Entry 9 (Conditions B)

Table 2, Entry 10 (Conditions A)

Table 2, Entry 10 (Conditions B)

Table 2, Entry 11 (Conditions A)

Table 2, Entry 11 (Conditions B)

Table 2, Entry 12 (Conditions A)

Table 2, Entry 12 (Conditions B)

Table 2, Entry 13 (Conditions A)

Table 2, Entry 13 (Conditions B)

Table 3, Entry 1

S125
S127
S129
S131
S133
S134
S135
S136
S137
S138
S139
S140
S141
S142
S143
S144
S145
S146
S147
S148
S149
S150
S151
S152
S153
S154
S155
S156
S157
S158
S159
S160
S161
S162
Table 6, Entry 5 (Conditions B) ........................................................................ S163
Table 6, Entry 5 (Conditions A) ........................................................................ S166
Table 6, Entry 6 ................................................................................................... S169
Table 6, Entry 7 ................................................................................................... S170
Table 6, Entry 8 ................................................................................................... S171
Table 6, Entry 9 ................................................................................................... S172
Table 4, Entry 1 (Conditions A) ........................................................................ S173
Table 4, Entry 1 (Conditions B) ........................................................................ S174
Table 4, Entry 2 (Conditions A) ........................................................................ S175
Table 4, Entry 2 (Conditions B) ........................................................................ S176
Table 4, Entry 3 (Conditions A) ........................................................................ S177
Table 4, Entry 3 (Conditions B) ........................................................................ S178
Table 4, Entry 4 (Conditions A) ........................................................................ S179
Table 4, Entry 4 (Conditions B) ........................................................................ S180
Table 4, Entry 5 (Conditions A) ........................................................................ S181
Table 4, Entry 5 (Conditions B) ........................................................................ S182
Table 4, Entry 6 (Conditions A) ........................................................................ S183
Table 4, Entry 6 (Conditions B) ........................................................................ S184
Table 5, Entry 1 ................................................................................................... S185
Table 5, Entry 2 ................................................................................................... S186
Table 6, Entry 1 (Conditions A) ........................................................................ S187
Table 6, Entry 1 (Conditions B) ........................................................................ S188
Table 6, Entry 2 (Conditions A) ........................................................................ S189
Table 6, Entry 2 (Conditions B) ........................................................................ S190
Table 6, Entry 3 (Conditions A) ........................................................................ S191
Table 6, Entry 3 (Conditions B) ........................................................................ S192
Table 6, Entry 4 (Conditions A) ........................................................................ S193
Table 6, Entry 4 (Conditions B) ........................................................................ S194
Table 6, Entry 5 (Conditions A) ........................................................................ S195
Table 6, Entry 5 (Conditions B) ........................................................................ S196
Table 6, Entry 6 (Conditions A) ........................................................................ S197
Experimental Note

All reagents were obtained from commercial sources and were used without further purification, unless otherwise stated. The following solvents were distilled prior to use, according to the following methods; THF was freshly distilled from sodium benzophenone ketyl, CH₂Cl₂ was distilled from phosphorus pentoxide and stored over 4 Å molecular sieves, MeOH was distilled from Mg/I₂ onto 3 Å molecular sieves. Room temperature (rt) ranged between 16.5–24 °C with an average value of 20 °C. Thin layer chromatography (TLC) and preparative TLC (PTLC) was carried out on pre-coated Merck silica gel GF254 plates, using UV₂54 nm light detection and/or basic aq. KMnO₄ staining. Molecular sieves (3 Å and 4 Å) were dried prior to use, by heating to 170 °C for 48 h. Wet flash column chromatography was performed using Merck Kieselgel 60 (particle size 0.040–0.063 mm, density 0.8 g/cm³).

Nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker Avance 400 MHz NMR spectrometer or Bruker Avance 300 MHz NMR spectrometer at 20 °C, using CDCl₃ (with tetramethylsilane [TMS] as internal standard, δH 0.00 ppm) or DMSO-d₆ as sample solvent. Chemical shift values (δH and δC) are reported in parts per million (ppm) relative to TMS (CDCl₃) and/or residual solvent (δH 2.50 [DMSO-d₆] or δH 7.26 [CDCl₃]) and coupling constants (J) are expressed in Hertz (Hz), in the following format; chemical shift value (integration, multiplicity, coupling constant). ¹H NMR spectral data are described, using the following abbreviations; s (singlet), brs (broad singlet), d (doublet), t (triplet), tq (triplet of quartets), q (quartet), quint (quintet), ddd (doublet of doublets of doublets), appsext (apparent sextet), and m (multiplet). ¹³C NMR spectral data was calibrated using residual solvent signals for CDCl₃ (δC 77.0, t) or DMSO-d₆ (δC 39.5, septet).

Melting point (m.p.) datum was obtained (uncorrected), using a Stuart® Analogue Melting Point Apparatus SMP11, for non-recrystallized solids (unless otherwise stated). Infrared (IR) spectra were obtained using a Perkin Elmer Spectrum Two FT-IR Spectrometer (Shelton, CT, USA). High-resolution mass spectrometry (HRMS) experiments were performed on a Waters Micromass LCT Premier® time-of-flight (TOF) mass spectrometer or a Waters Vion IMS QTOF mass spectrometer using electrospray ionization (ESI). The eluent system employed for HRMS analysis consisted of MeCN/H₂O (1:1) and contained 0.1% v/v formic acid. HRMS experiments were performed using leucine enkephalin as an internal calibrant.
Synthesis of C-3 substituted 1H-indazoles

1H-Indazole-3-carboxylic acid

A chilled solution of isatin (12.098 g, 82.23 mmol) in aq. NaOH (3.618 g, 90.45 mmol, 25 mL H₂O) was stirred at room temperature for 10 min (complete consumption of isatin was observed by TLC [EtOAc, Rᵣ = 0.80]). The resulting pale orange solution was cooled to 0 °C and slowly charged with aq. NaNO₂ (5.674 g, 82.23 mmol, 25 mL H₂O) at 0 °C. The combined aq. solution was then slowly transferred (temperature < 4 °C) via cannula to a stirred solution of aq. H₂SO₄ (8.74 mL, 164.46 mmol, in 150 mL H₂O) at 0 °C. Upon completion of addition, the resulting mixture was stirred at 0 °C for a further 15 min to afford a tan brown mixture. To control foaming, Et₂O was occasionally added dropwise to the reaction mixture. The diazonium salt solution was then slowly introduced via cannula (temperature < 4 °C) to a vigorously stirred solution of SnCl₂•2H₂O (46.385 g, 205.58 mmol) in conc. HCl (75 mL, 12.1 M) at 0 °C. Upon complete addition of the diazonium salt solution, the reaction mixture was left to stir for 1 h at 0 °C. Filtration of the resulting pale yellow suspension under vacuum furnished a bright yellow solid wet cake which was further dried under vacuum in the presence of P₂O₅ overnight to give 1H-indazole-3-carboxylic acid as a fine bright yellow solid (13.334 g, 99%). A portion of the title compound was further purified by recrystallization from DMF/CH₂Cl₂ for spectral characterization: m.p. 268 °C (DMF/CH₂Cl₂) (lit. m.p. 265–265.5 °C [AcOH]) [1]; IR (ATR, cm⁻¹) νmax 3187, 2939, 1687, 1626, 1474, 1241, 738; ¹H NMR (400 MHz, DMSO-d₆) δ 13.79 (1H, brs), 12.97 (1H, brs), 12.08 (1H, d, J = 8.2 Hz), 7.64 (1H, d, J = 8.4 Hz), 7.43 (1H, ddd, J = 7.9, 7.1, 0.8 Hz), 7.28 (1H, t, J = 7.5 Hz); ¹³C NMR (100 MHz, DMSO-d₆) δ 163.9, 141.1, 136.0, 126.6, 122.6, 122.4, 121.3, 111.1; HRMS (ESI) m/z [M–H]⁻ Calcd for C₈H₆N₂O₂ 161.0357, found 161.0349 (− 5.0 ppm). Spectral data were in agreement with literature values [2].
$^1$H NMR (400 MHz, DMSO-$d_6$)

$^{13}$C NMR (100 MHz, DMSO-$d_6$)
Methyl 1\(H\)-indazole-3-carboxylate (9)

![](image)

\(1H\)-Indazole-3-carboxylic acid (9 g, 55.5 mmol), in MeOH (277.5 mL, 0.2 M) was treated with conc. \(H_2SO_4\) (1 mL, 18.4 mmol) and heated to reflux for 24 h. The resulting orange solution was concentrated in vacuo. The crude product was then reconstituted in EtOAc (150 mL) and washed with sat. aq. NaHCO\(_3\) (50 mL), water (50 mL), and brine (50 mL). The resulting organic layer was then dried over MgSO\(_4\) and concentrated under reduced pressure to afford title compound 9 as a bright yellow solid. Recrystallization from EtOAc/hexane (1:3) furnished the ester as a beige solid (8.585 g, 88%): m.p. 165–167.9 °C (EtOAc/hexane) [lit. m.p. 168–170 °C [EtOAc/hexane]][3]; IR (ATR, cm\(^{-1}\)) \(\nu_{\text{max}}\) 3216, 3184, 3088, 3007, 2951, 1732, 1479, 1232, 1149, 746; \(^1\)H NMR (400 MHz, CDCl\(_3\)) \(\delta\) 13.05 (1H, brs), 8.22 (1H, d, \(J = 8.2\) Hz), 7.77 (1H, d, \(J = 8.4\) Hz), 7.47 (1H, t, \(J = 7.5\) Hz), 7.34 (1H, t, \(J = 7.5\) Hz), 4.08 (3H, s); \(^{13}\)C NMR (100 MHz, CDCl\(_3\)) \(\delta\) 163.5, 141.4, 136.3, 127.4, 123.3, 122.4, 121.7, 111.2, 52.1; HRMS (ESI) \(m/z\) [M+H]\(^+\) Calcd for \(C_9H_9N_2O_2\) 177.0659, found 177.0661 (1.1 ppm). Spectral data were in agreement with literature values [4].
$^1$H NMR (400 MHz, CDCl$_3$) 9

$^{13}$C NMR (100 MHz, CDCl$_3$) 9
To a 500 mL round bottom flask containing a cooled (−5 °C) solution of α-toluidine (22.01 mL, 209 mmol) in 3.2 M aq. HCl (52.25 mL conc. HCl [628 mmol] in 198.55 mL H₂O) was added NaNO₂ (14.421 g, 209 mmol) in H₂O (33.44 mL) dropwise (reaction mass temperature was maintained between −4 °C and 2 °C). The mixture was stirred for a further 30 min (temperature < 0 °C) and then filtered. The filtrate was then charged with aq. NaBF₄ (25.252 g, 230 mmol in 94.1 mL H₂O) and stirred at 0 °C for a further 40 min. The resulting solid was then isolated, using vacuum filtration, to afford a solid wet cake which was subsequently washed with cold EtOH (50 mL × 3) and cold Et₂O (50 mL × 3). The colorless solid was then added portion-wise to a stirred solution of KOAc (32.473 g, 331 mmol) and 18-crown-6 (2.036 g, 8 mmol) in CHCl₃ (600 mL, 0.35 M) in a 1 L vessel (fitted with a Liebig condenser) at room temperature. After 2 h, the crimson suspension was filtered under reduced pressure. The solids were further washed with CHCl₃ (250 mL × 3) and the resulting filtrate was dried over Na₂SO₄ prior to solvent removal under reduced pressure to give crude 12 as a brown gum (18.964 g). Recrystallization from H₂O gave 12 as a beige crystalline solid (7.4 g, 30%): m.p. 143–143.5 °C (H₂O) [lit. m.p. 143–144 °C [H₂O]]; IR (ATR, cm⁻¹) νₘₐₓ 3178, 3156, 1621, 1504, 1356, 952, 845, 739; ¹H NMR (400 MHz, CDCl₃) δ 10.76 (1H, brs), 8.13 (1H, s), 7.78 (1H, d, J = 8.1 Hz), 7.52 (1H, d, J = 8.2 Hz), 7.40 (1H, t, J = 7.3 Hz), 7.18 (1H, t, J = 7.5 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 140.0, 134.8, 126.8, 123.2, 121.0, 120.9, 109.7; HRMS (ESI) m/z [M+H]+ Calcd for C₇H₇N₂ 119.0604, found 119.0606 (1.7 ppm). Spectral data were in agreement with literature values [2].

---

**1H-indazole (12)**

![Chemical structure of 1H-indazole (12)](image_url)
\(^1\)H NMR (400 MHz, CDCl\(_3\)) 12

\[^{13}\]C NMR (100 MHz, CDCl\(_3\)) 12
3-(o-Tolyldiazenyl)-1H-indazole

Using wet flash column chromatography (EtOAc/hexane, 1:4), the title compound ($R_f = 0.27$) was isolated from the crude reaction mixture of indazole 12 as a brilliant yellow solid (1.481 g, 3%): m.p. 207–208.5 °C (xylene) (lit. m.p. 211–211.5 °C [xylene][6]; IR (ATR, cm$^{-1}$) $\nu_{max}$ 3152, 3122, 3070, 3048, 2980, 2921, 2885, 2851, 1629, 1486 (N=N), 1374, 739, 713; $^1$H NMR (400 MHz, DMSO-d$_6$) $\delta$ 13.94 (1H, brs), 8.28 (1H, d, $J = 8.1$ Hz), 7.70 (1H, d, $J = 7.9$ Hz), 7.65 (1H, d, $J = 8.4$ Hz), 7.50 (1H, t, $J = 7.6$ Hz), 7.48–7.42 (2H, m), 7.42–7.34 (2H, m), 2.75 (3H, s); $^{13}$C NMR (100 MHz, DMSO-d$_6$) $\delta$ 155.9, 150.6, 141.4, 137.4, 131.4, 131.2, 127.5, 126.7, 124.2, 122.4, 114.3, 112.8, 110.7, 17.6; HRMS (ESI) $m/z$ [M+H]$^+$ Calcd for C$_{14}$H$_{13}$N$_4$ 237.1140, found 237.1137 (– 1.3 ppm).
$^1$H NMR (400 MHz, DMSO-$d_6$)

$^{13}$C NMR (100 MHz, DMSO-$d_6$)
3-tert-Butyl-1H-indazole (14)

To an oven dried two neck 100 mL round bottom flask flush with \( N_2 \) was added 2 M \( t\)-BuMgCl in Et\(_2\)O (11 mL, 22 mmol) and THF (33 mL). The mixture was then treated dropwise with a solution of 2-fluorobenzaldehyde (2.11 mL, 20 mmol). The resulting solution was allowed to stir under an inert atmosphere at rt for a further 24 h. The reaction was then cooled to 0 °C and treated dropwise with sat. aq. \( \text{NH}_4\text{Cl} \) (1 mL). After stirring for 30 min, the reaction mass was concentrated in vacuo.

The resulting residue was taken up in CH\(_2\)Cl\(_2\) (50 mL) and washed with \( \text{H}_2\text{O} \) (25 mL × 2) and brine (25 mL). The organic layer was then dried over MgSO\(_4\) and concentrated under reduced pressure.

The resulting yellow oil was dissolved in CH\(_2\)Cl\(_2\) (6 mL) and then slowly added to a stirring solution of PCC (3.880 g, 18 mmol) and silica (3.880 g) in CH\(_2\)Cl\(_2\) (24 mL) and allowed to stir under an inert atmosphere for 4 h. The resulting black suspension was then filtered through a short pad of silica and eluted with CH\(_2\)Cl\(_2\). The resulting solution was concentrated under vacuum to give an amber oil which was then transferred to a microwave vessel and containing a stir bar and hydrazine hydrate (5 mL [80% in H\(_2\)O, \( \approx \) 51% hydrazine]) and allowed to stir at 175 °C for 30 min in a Discover SP\(^\text{®}\) microwave reactor (CEM). The resulting mixture was then poured onto ice (15 mL) and allowed to stir for a further 30 min. The aqueous layer was then extracted with CH\(_2\)Cl\(_2\) (10 mL × 3). The organic phases were combined, dried over MgSO\(_4\), and concentrated in vacuo to give crude 14 a beige solid. Iterative recrystallization from EtOAc/hexane (1:10) subsequently furnished title compound 14 as a colorless solid (467 mg, 13%): m.p. 190–191 °C (EtOAc/hexane) (lit. m.p. 152–154 °C)[7]; IR (ATR, cm\(^{-1}\)) \( \nu_{\text{max}} \) 3144, 3110, 2963, 2927, 2898, 1341, 1052, 774, 737, 429; \(^1\)H NMR (300 MHz, CDCl\(_3\)) \( \delta \) 9.10 (1H, brs), 7.90 (1H, ddd, \( J = 8.2, 1.9, 0.9 \) Hz), 7.43 (1H, ddd, \( J = 8.4, 1.9, 0.9 \) Hz), 7.34 (1H, ddd, \( J = 7.8, 6.8, 1.0 \) Hz), 7.11 (1H, ddd, \( J = 8.2, 6.9, 1.1 \) Hz), 1.54 (9H, s); \(^{13}\)C NMR (75 MHz, CDCl\(_3\)) \( \delta \) 154.6, 141.9, 126.2, 122.1, 120.5, 119.8, 110.0, 33.8, 30.0; HRMS (ESI) \( m/z \) [M+H]\(^+\) Calcd for C\(_{11}\)H\(_{15}\)N\(_2\) 175.1230, found 175.1228 (− 1.1 ppm). Spectral data were in agreement with literature values [7].
$^1$H NMR (300 MHz, CDCl$_3$) 14

$^{13}$C NMR (75 MHz, CDCl$_3$) 14
To a 20 mL microwave reaction vial was added 2-fluorobenzaldehyde (0.42 mL, 4 mmol) and 80% aq. hydrazine hydrate (1.6 mL, 25 mmol [50–60% hydrazine], 0.3 M). The vessel was then placed in a Discover SP® microwave reactor (CEM) and heated to 175 °C for 30 min. Upon cooling to room temperature, the reaction mass was then diluted with water (30 mL) and extracted with CH₂Cl₂ (10 mL × 3). The combined organic phases were then washed with brine (10 mL), dried over MgSO₄, and concentrated in vacuo to give a colorless oil which was allowed to stand at room temperature overnight. The resulting orange solid was then further purified using wet flash column chromatography (EtOAc/hexane, 1:9) to furnish title compound 15 (Rᵣ = 0.14) as a colorless oil (567 mg, 73%) which solidified on standing at room temperature overnight to give a beige solid: m.p. 110 °C (lit. m.p. 108–111 °C)[8]; IR (ATR, cm⁻¹) νₘₐₓ 3150, 2933, 1344, 774, 736, 694, 427; ¹H NMR (400 MHz, CDCl₃) δ 11.73 (1H, brs), 8.04–7.98 (3H, m), 7.55–7.51 (2H, m), 7.47–7.43 (1H, m), 7.27 (1H, ddd, J = 8.1, 6.9, 0.8 Hz), 7.17 (1H, ddd, J = 8.0, 6.9, 0.8 Hz), 7.04 (1H, d, J = 8.5 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 145.7, 141.7, 133.6, 129.0, 128.2, 127.8, 126.8, 121.4, 121.1, 121.0, 110.3; HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₃H₁₁N₂ 195.0917, found 195.0918 (0.5 ppm). Spectral data were in agreement with literature values [8].
$^1$H NMR (400 MHz, CDCl$_3$) 15

$^{13}$C NMR (100 MHz, CDCl$_3$) 15
3-Iodo-1H-indazole (16)

To a 500 mL round bottom flask containing 1H-indazole (12, 7.4 g, 63 mmol) and I₂ (15.989 g, 126 mmol) in DMF (190 mL), at 0 °C, was added portion wise KOH (7.071 g, 126 mmol). The mixture was allowed to warm to room temperature and stirred for a further 4 h. The reaction mass was then treated with sat. aq. Na₂S₂O₃ (500 mL), diluted with H₂O (250 mL), and extracted with EtOAc (100 mL × 5). The combined organic layers were then washed with brine (250 mL × 3), dried over anhydrous Na₂SO₄, and concentrated in vacuo to give a crude brown solid residue which was further purified using wet flash column chromatography (EtOAc/hexane, 1:4) to afford the title compound 16 (Rᵣ = 0.46) as a colorless amorphous solid (9.309 g, 61%): m.p. 142 °C (lit. m.p. 142–143 °C)[9]; IR (ATR, cm⁻¹) νₘₐₓ 3156, 2936, 1621, 1473, 1345, 1239, 1014, 900, 770, 738, 634; ¹H NMR (400 MHz, CDCl₃) δ 12.42 (1H, brs), 7.72 (1H, d, J = 8.6 Hz), 7.52 (1H, d, J = 8.2 Hz), 7.47 (1H, ddd, J = 8.0, 7.2, 0.8 Hz), 7.23 (1H, t, J = 7.4 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 140.6, 128.1, 127.4, 121.8, 121.3, 110.6, 93.5; HRMS (ESI) m/z [M+H]^⁺ Calcd for C₇H₅IN₂ 244.9570, found 244.9574 (1.6 ppm). Spectral data were in agreement with literature values [9].
$^1$H NMR (400 MHz, CDCl$_3$) 16

$^{13}$C NMR (100 MHz, CDCl$_3$) 16
3-Bromo-1H-indazole (17)

To a 50 mL round bottom flask was added 1H-indazole (12, 591 mg, 5 mmol) and DMF (10 mL). The resulting solution was then cooled to 0 °C and subsequently treated dropwise with bromine (0.38 mL, 7.41 mmol). The reaction mass was then warmed to room temperature and allowed to stir for a further 2 h. The resulting deep brown solution was then diluted with EtOAc (30 mL) and washed with brine (60 mL), sat. aq. Na₂S₂O₃ (60 mL), and brine (60 mL × 2). The resulting organic layer was dried over MgSO₄ and concentrated in vacuo to afford crude 17 as a beige solid. Wet flash column chromatography (EtOAc/hexane, 1:3) furnished title compound 17 (RF = 0.43) as colorless solid (729 mg, 74%): m.p. 119 °C (lit. m.p. 120–122 °C)[10]; IR (ATR, cm⁻¹) ν_max 3156, 3129, 2945, 1625, 1480, 1331, 1243, 1026, 902, 771, 734, 640; ¹H NMR (400 MHz, CDCl₃) δ 11.19 (1H, brs), 7.67 (1H, d, J = 8.2 Hz), 7.59 (1H, d, J = 8.5 Hz), 7.47 (1H, ddd, J = 8.2, 7.1, 1.0 Hz), 7.25 (1H, ddd, J = 7.7, 7.0, 0.7 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 141.2, 128.2, 123.1, 122.9, 121.9, 120.2, 110.4; HRMS (ESI) m/z [M+H]+ Calcd for C₇H₅BrN₂ 196.9709, found 196.9712 (0.9 ppm). Spectral data were in agreement with literature values [10].
$^1$H NMR (400 MHz, CDCl$_3$) 17

$^{13}$C NMR (100 MHz, CDCl$_3$) 17
3-Nitro-1H-indazole (19)

To a 50 mL round bottom flask was added 1H-indazole (12, 2.362 g, 20 mmol) and AcOH (16.6 mL). The mixture was allowed to stir for a further 15 min at room temperature, prior to the addition of conc. HNO₃ (1.02 mL, 22.8 mmol). The resulting beige suspension was then heated to 40 °C for 15 min. The reaction mixture was then treated with Ac₂O (2.74 mL, 24.84 mmol) and heated to 50 °C for 30 min. Upon cooling to room temperature, the reaction mass was treated with ice cold H₂O (60 mL) and allowed to stir for a further 1 h. The suspension was then filtered under vacuum to afford the crude product as a solid wet cake which was further purified using wet flash column chromatography (EtOAc/CHCl₃, 1:3) to afford title compound 19 (Rᵣ = 0.58) as beige solid (1.139 g, 35%): m.p. 204–205 °C (lit. m.p. 205 °C)[4]; IR (ATR, cm⁻¹) νₓₘₐₓ 3196, 3170, 3058, 2945, 2907, 1531, 1381, 1322, 1249, 831, 777, 744, 427; ¹H NMR (300 MHz, DMSO-d₆) δ 14.45 (1H, brs), 8.11 (1H, d, J = 8.2 Hz), 7.75 (1H, d, J = 8.4 Hz), 7.57 (1H, ddd, J = 8.1, 6.9, 1.1 Hz), 7.48 (1H, ddd, J = 7.9, 7.0, 0.8, Hz); ¹³C NMR (75 MHz, DMSO-d₆) δ 148.2, 141.4, 128.1, 125.4, 120.0, 115.2, 112.0; HRMS (ESI) m/z [M–H]⁻ Calcd for C₇H₄N₃O₂ 162.0309, found 162.0301 (−4.9 ppm). Spectral data were in agreement with literature values [4].
$^1$H NMR (300 MHz, DMSO-$d_6$) 19

![NMR spectrum of compound 19 showing proton signals at various ppm values.](image)

$^{13}$C NMR (75 MHz, DMSO-$d_6$) 19

![NMR spectrum of compound 19 showing carbon signals at various ppm values.](image)
1H-Indazole-3-carboxaldehyde (21)

Aqueous HCl (4 mL, 2 M, 8.1 mmol) was slowly added (0.3 mL/min) to a cold (0 °C) solution of NaNO₂ (1.656 g, 24 mmol) in H₂O/DMF (12 mL H₂O, 9 mL DMF; 4:3) under a nitrogen atmosphere and left to stir for a further 10 min at 0 °C. 1H-Indole (351 mg, 3 mmol) in DMF (9 mL) was then slowly added (75 µL/min) to the flask over 2 h at 0 °C. The resulting mixture was stirred at room temperature for 3 h and then treated with toluene and the solvent removed under reduced pressure to afford a crude dark orange solid (2.279 g). The solid was then dissolved with CH₂Cl₂ (35 mL) and repeatedly washed with H₂O (50 mL × 3). The resulting organic layer was dried over MgSO₄ and concentrated in vacuo to give the title compound 21 as a brown solid (388 mg, 89%): m.p. 138 °C (lit. m.p. 141 °C)[11]; IR (ATR, cm⁻¹) νₘₐₓ 3184, 3161, 2953, 1668, 1087, 794, 738; ¹H NMR (400 MHz, CDCl₃) δ 11.51 (1H, brs), 10.34 (1H, s), 8.32 (1H, d = 8.1 Hz), 7.62 (1H, d, J = 8.4 Hz), 7.50 (1H, t, J = 7.6 Hz), 7.37 (1H, t, J = 7.5 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 187.5, 144.8, 141.2, 128.1, 124.3, 122.0, 121.0, 110.1; HRMS (ESI) m/z [M+H]+ Calcd for C₉H₇N₂O 147.0553, found 147.0552 (– 0.5 ppm). Spectral data were in agreement with literature values [11].
$^1$H NMR (400 MHz, CDCl$_3$) 21

$^{13}$C NMR (100 MHz, CDCl$_3$) 21
**N-Methyl-1*H*-indazole-3-carboxamide (23)**

To an oven-dried 50 mL round bottom flask flushed with N₂ was added 1*H*-indazole-3-carboxylic acid (500 mg, 3.08 mmol) and SOCl₂ (5 mL, 68.9 mmol). The mixture was then heated to reflux and stirred for 2 h. The resulting mixture was then allowed to cool to room temperature and concentrated in vacuo to give an oily residue which was dissolved in THF (15.4 mL, 0.2 M) and subsequently treated dropwise with NEt₃ (0.86 mL, 6.17 mmol) and methylamine HCl (1.04 g, 15.4 mmol). The resulting dark brown suspension was allowed to stir under a nitrogen atmosphere at room temperature for a further 24 h. The yellow reaction mixture was then concentrated under reduced pressure to afford an oily residue which was taken up in CHCl₃ (30 mL) and washed with aq. 0.2 M aq. HCl (10 mL). The aqueous layer was subsequently extracted with CHCl₃ (5 mL × 2). The combined organic phases were then washed with brine (10 mL), dried over MgSO₄, and concentrated in vacuo to give a pale orange solid which was triturated with CH₂Cl₂ (5 mL) and filtered to give title compound 23 as fine beige solid (381 mg, 71%, over two steps): m.p. 174–175 °C; IR (ATR, cm⁻¹) νmax 3346, 3307, 3149, 3117, 3072, 2777, 1634, 1548, 1466, 1347, 1237, 1157, 984, 783, 673, 427; ¹H NMR (400 MHz, DMSO-d₆) δ 13.55 (1H, brs), 8.36 (1H, d, J = 4.4, Hz), 8.18 (1H, d, J = 8.1 Hz), 7.60 (1H, d, J = 8.4 Hz), 7.40 (1H, t, J = 7.6 Hz), 7.23 (1H, t, J = 7.5 Hz), 2.82 (3H, d, J = 4.7 Hz); ¹³C NMR (100 MHz, DMSO-d₆) δ 162.7, 141.0, 138.4, 126.4, 121.9, 121.6, 121.4, 110.6, 25.5; HRMS (ESI) m/z [M+H]+ Calcd for C₉H₁₀N₃O 176.0818, found 176.0822 (2.3 ppm).
(1H-Indazol-3-yl)(pyrrolidin-1-yl)methanone (24)

To a 20 mL microwave reaction vial was added methyl ester 9 (1 g, 5.68 mmol) and pyrrolidine (4 mL, 48.7 mmol). The vessel was then placed in a Discover SP® microwave reactor (CEM) and heated to 100 °C and stirred for 1 h. Upon cooling to room temperature, the resulting solution was concentrated in vacuo to give an orange oily solid. The crude product was then triturated with CH₂Cl₂ (10 mL) and the resulting solids filtered under vacuum to afford title compound 24 as a fine beige solid (1.043 g, 85%): m.p. 193–194 °C (EtOH); IR (ATR, cm⁻¹) νmax 3151, 3118, 3047, 2969, 2925, 2887, 1589, 1566, 1488, 1466, 1450, 1341, 1320, 1147, 764, 735, 433; ¹H NMR (300 MHz, DMSO-d⁶) δ 13.42 (1H, brs), 8.15 (1H, d, J = 8.2 Hz), 7.60 (1H, d, J = 8.4 Hz), 7.40 (1H, ddd, J = 8.3, 7.0, 1.1 Hz), 7.21 (1H, ddd, J = 7.9, 7.1, 0.8 Hz), 3.94 (2H, t, J = 6.5 Hz), 3.57 (2H, t, J = 6.6 Hz), 1.96–1.79 (4H, m); ¹³C NMR (75 MHz, DMSO-d₆) δ 161.5, 140.3, 139.5, 126.4, 122.9, 122.0, 121.6, 110.3, 48.4, 46.4, 26.1, 23.4; HRMS (ESI) m/z [M–H]⁺ Calcd for C₁₂H₁₄N₃O 216.1131, found 216.1122 (− 4.2 ppm).
$^1$H NMR (300 MHz, DMSO-$d_6$) 24

$^{13}$C NMR (75 MHz, DMSO-$d_6$) 24
1H-indazole N-alkylation

General Procedure (A):

\[
\text{R}^1\text{N} = \text{H} 
\text{NaH, R}^2\text{-X} \rightarrow \text{THF, N}_2, 0 \, ^\circ\text{C} \rightarrow 50 \, ^\circ\text{C}, 24 \, \text{h}
\]

To an oven-dried 50 mL round bottom flask was added the appropriately substituted indazole (1 mmol) and THF (5 mL). The resulting solution was cooled to 0 °C and treated with NaH (26 mg, 1.1 mmol) and allowed to stir at 0 °C for a further 1 h. To the cooled suspension was added alkylation reagent, R\(^2\)-X (1.2 mmol). The mixture was heated to 50 °C for a further 24 h. The reaction mass was treated with MeOH (2.5 mL) and concentrated under reduced pressure. The resulting crude residue was dissolved in EtOAc (25 mL), washed with sat. aq. Na\(_2\)S\(_2\)O\(_3\) (10 mL), H\(_2\)O (10 mL), and brine (10 mL). The organic layer was dried over MgSO\(_4\) and concentrated in vacuo to give the crude product which was further purified using wet flash column chromatography to furnish the corresponding N-alkylated indazole(s).

General Procedure (B):

\[
\text{R}^1\text{N} = \text{H} 
\text{Cs}_2\text{CO}_3, \text{R}^2\text{-X} \rightarrow \text{DMF, rt, 16 h}
\]

To a 50 mL round bottom flask was added the appropriately substituted indazole (1 mmol) and DMF (5 mL). The resulting solution was treated with Cs\(_2\)CO\(_3\) (489 mg, 1.5 mmol) and allowed to stir at room temperature for a further 30 min. To the suspension was added alkylation reagent, R\(^2\)-X (1.2 mmol), and the mixture was stirred at room temperature for a further 16 h. The reaction mass was diluted with EtOAc (20 mL) and washed with brine (40 mL), sat. aq. Na\(_2\)S\(_2\)O\(_3\) (10 mL) and brine (40 mL × 2). The organic layer was dried over MgSO\(_4\) and concentrated under reduced pressure to afford crude product which was further purified using wet flash column chromatography to yield the corresponding N-alkylated indazole(s).
Note: Order of Elution of N-1 and N-2 Regioisomers using Wet Flash Column Chromatography

Following General Procedure A or B, the N-1 regioisomer typically eluted before the corresponding N-2 regioisomer, using wet flash column chromatography. However, the order of elution was reversed for 1H-indazole and analogous derivatives bearing a nitro or carboxymethyl substituent at the C-3 position, where the N-2 regioisomer eluted first and was then followed by the corresponding N-1 regioisomer.

Methyl 1-n-pentyl-1H-indazole-3-carboxylate (10)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:4) furnished title compound 10 (Rf = 0.40) as a yellow oil: IR (ATR, cm⁻¹) νmax 2955, 2932, 2861, 1709, 1616, 1477, 1215, 1158, 1117, 750, 643, 432; ¹H NMR (400 MHz, CDCl₃) δ 8.24 (1H, d, J = 8.2 Hz), 7.48 (1H, d, J = 8.4 Hz), 7.44 (1H, ddd, J = 7.3, 6.5, 0.8 Hz), 7.32 (1H, ddd, J = 7.9 Hz, 6.8, 1.1 Hz), 4.47 (2H, t, J = 7.4 Hz), 4.04 (3H, s), 1.97 (2H, quint, J = 7.4 Hz), 1.40–1.25 (4H, m), 0.88 (3H, t, J = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 163.1, 140.4, 134.4, 126.7, 123.7, 123.0, 122.2, 109.6, 52.0, 50.0, 29.6, 28.9, 22.2, 13.9; HRMS (ESI) m/z [M+H]+ Calcd for C₁₄H₁₉N₂O₂ 247.1441, found 247.1442 (0.4 ppm). Spectral data were in agreement with literature values [3].
$^1$H NMR (400 MHz, CDCl$_3$) 10

$^{13}$C NMR (100 MHz, CDCl$_3$) 10
Methyl 2-\textit{n}-pentyl-2\textit{H}-indazole-3-carboxylate (11)

Following \textbf{General Procedure A} and/or \textbf{B}, wet flash column chromatography (EtOAc/hexane, 1:4) furnished title compound 11 ($R_f = 0.63$) as a yellow oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 2955, 2931, 2861, 1710, 1464, 1278, 1205, 1077, 758, 434; $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 8.02 (1H, d, $J = 8.3$ Hz), 7.79 (1H, d, $J = 8.6$ Hz), 7.35 (1H, t, $J = 7.6$ Hz), 7.28 (1H, t, $J = 7.9$ Hz), 4.90 (2H, t, $J = 7.5$ Hz), 1.97 (2H, quint, $J = 7.4$ Hz), 1.38–1.37 (4H, m), 0.90 (3H, t, $J = 6.4$ Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 160.7, 147.3, 126.2, 124.9, 123.5, 123.3, 121.4, 118.2, 53.8, 51.9, 30.7, 28.8, 22.3, 14.0; HRMS (ESI) $m/z$ [M+H]$^+$ Calcd for C$_{14}$H$_{19}$N$_2$O$_2$ 247.1441, found 247.1445 (1.6 ppm). Spectral data were in agreement with literature values [12].
$^{1}H$ NMR (400 MHz, CDCl$_3$) 11

$^{13}$C NMR (100 MHz, CDCl$_3$) 11
**N-Alkylation of Methyl Ester 9 under Mitsunobu Conditions**

To an oven-dried 50 mL round bottom flask was added DBAD (261 mg, 1.5 mmol) and THF (10 mL). The resulting bright yellow solution was cooled to 0 °C and then treated with PPh₃ (393 mg, 1.5 mmol) and allowed to stir for a further 30 min at 0 °C. The resulting colorless mixture was treated with *n*-pentanol (0.11 mL, 1 mmol) and ester 9 (264 mg, 1.5 mmol). The reaction mixture was warmed to room temperature and allowed to stir for a further 2 h. The resulting solution was concentrated under reduced pressure to afford a viscous amber oil. The crude residue was dissolved in CHCl₃ (5 mL) and treated dropwise with CF₃CO₂H (1.5 mL, 15 mmol) and stirred for 18 h at room temperature. The resulting solution was concentrated under reduced pressure and redissolved in EtOAc (25 mL). The organic phase was then washed with sat. aq. NaHCO₃ (10 mL × 2), H₂O (10 mL), brine (10 mL), dried over MgSO₄, and concentrated under reduced pressure to afford crude product which was further purified using wet flash column chromatography (EtOAc/hexane, 1:4) to give *N*-1 regioisomer 10 (*R*₁ = 0.40) as a colorless oil (49 mg, 20%) and the corresponding *N*-2 regioisomer 11 (*R*₁ = 0.63) as a colorless oil (143 mg, 58%).
1-\textit{n}-Pentyl-1\textit{H}-indazole (25)

Following **General Procedure A** and/or **B**, wet flash column chromatography (EtOAc/hexane, 1:19) gave the title compound 25 ($R_f = 0.10$) as an amber oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3061, 2956, 2930, 2871, 2859, 1616, 1475, 751, 737, 635, 428; $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 7.99 (1H, d, $J = 0.8$ Hz), 7.73 (1H, ddd, $J = 8.1$, 1.9, 1.0 Hz), 7.42–7.35 (2H, m), 7.14 (1H, ddd, $J = 7.8$, 6.6, 1.2 Hz), 4.38 (2H, t, $J = 7.2$ Hz), 1.93 (2H, quint, $J = 7.3$ Hz), 1.40–1.26 (4H, m), 0.86 (3H, t, $J = 7.0$ Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 139.4, 132.7, 126.0, 124.0, 121.1, 120.3, 109.0, 48.9, 29.6, 29.0, 22.3, 14.0; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{12}$H$_{17}$N$_2$ 189.1386; found 138.1382 (− 2.4 ppm). Spectral data were in agreement with literature values [13].
$^1$H NMR (400 MHz, CDCl$_3$) 25

$^{13}$C NMR (100 MHz, CDCl$_3$) 25
2-\textit{n}-Pentyl-2\textit{H}-indazole (26)

Following **General Procedure A** and/or **B**, wet flash column chromatography (EtOAc/hexane, 1:19) gave the title compound 26 ($R_f = 0.23$) as colorless oil: IR (ATR, cm$^{-1}$) $\nu_{max}$ 3099, 3060, 2955, 2931, 2860, 1628, 1156, 1140, 781, 754, 732, 432; $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 7.88 (1H, s), 7.72 (1H, dd, $J = 8.7$, 0.8 Hz), 7.64 (1H, d, $J = 8.4$ Hz), 7.27 (1H, ddd, $J = 8.7$, 6.7, 1.1 Hz), 7.07 (1H, ddd, $J = 8.4$, 6.6, 0.9 Hz), 4.38 (2H, t, $J = 7.2$ Hz), 2.00 (2H, quint, $J = 7.4$ Hz), 1.40–1.25 (4H, m), 0.88 (3H, t, $J = 7.1$ Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 148.7, 125.6, 122.4, 121.6, 121.4, 120.0, 117.3, 53.7, 30.3, 28.7, 22.1, 13.8; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{12}$H$_{17}$N$_2$ 189.1386; found 189.1379 (−3.4 ppm). Spectral data were in agreement with literature values [13].
3-Methyl-1-n-pentyl-1H-indazole (27)

Following **General Procedure A** and/or **B**, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound **27** ($R_f = 0.67$) as a colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3058, 2956, 2928, 2859, 1615, 1506, 1454, 1349, 1184, 1135, 1078, 1009, 739, 430; $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 7.64 (1H, d, $J = 8.1$ Hz), 7.37–7.32 (2H, m), 7.09 (1H, ddd, $J = 7.1$, 5.4, 2.3 Hz), 4.29 (2H, t, $J = 7.2$ Hz), 2.57 (3H, s), 1.89 (2H, quint, $J = 7.4$ Hz), 1.37–1.26 (4H, m), 0.87 (3H, t, $J = 7.0$ Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 141.0, 140.2, 125.9, 123.1, 120.3, 119.4, 108.8, 48.6, 29.7, 29.0, 22.3, 13.9, 11.9; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{13}$H$_{19}$N$_2$ 203.1543, found 203.1545 (1.1 ppm).
$\text{H NMR (400 MHz, CDCl}_3\text{) 27}$

$\text{C NMR (100 MHz, CDCl}_3\text{) 27}$
3-Methyl-2-n-pentyl-2H-indazole (28)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 28 ($R_f = 0.43$) as an amber oil: IR (ATR, cm\(^{-1}\)) $\nu_{max}$ 3058, 3019, 2955, 2929, 2860, 1630, 1455, 1366, 740, 433; $^1$H NMR (400 MHz, CDCl\(_3\)) $\delta$ 7.64 (1H, d, $J = 8.7$ Hz), 8.40 (1H, d, $J = 8.4$ Hz), 7.25 (1H, ddd, $J = 7.8$, 6.7, 0.8 Hz), 7.03–6.99 (1H, m), 4.31 (2H, t, $J = 7.4$ Hz), 2.59 (3H, s), 1.94 (2H, quint, $J = 7.4$ Hz), 1.40–1.25 (4H, m), 0.89 (3H, t, $J = 6.9$ Hz); $^{13}$C NMR (100 MHz, CDCl\(_3\)) $\delta$ 147.6, 130.6, 125.8, 120.9, 120.1, 119.5, 117.0, 50.2, 30.1, 28.8, 22.2, 13.9, 9.8; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C\(_{13}\)H\(_{19}\)N\(_2\) 203.1543, found 203.1542 (– 0.3 ppm).
3-tert-Butyl-1-n-pentyl-1H-indazole (29)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:9) gave the title compound 29 (Rf = 0.53) as a colorless oil: IR (ATR, cm⁻¹) νmax 3054, 2958, 2928, 2870, 1612, 1500, 738, 430; ¹H NMR (300 MHz, CDCl₃) δ 7.86 (1H, d, J = 8.2 Hz), 7.35–7.24 (2H, m), 7.05 (1H, ddd, J = 8.0, 5.9, 1.9 Hz), 4.29 (2H, t, J = 7.3 Hz), 1.87 (2H, quint, J = 7.3 Hz), 1.52 (9H, s), 1.40–1.24 (4H, m), 0.88 (3H, t, J = 6.9 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 152.3, 140.9, 125.3, 122.3, 121.1, 119.9, 109.1, 48.5, 30.3, 29.5, 29.1, 22.3, 14.0; HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₆H₂₅N₂ 245.2012, found 245.2012 (0.0 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 29

$^{13}$C NMR (75 MHz, CDCl$_3$) 29
3-Phenyl-1-n-pentyl-1H-indazole (31)

Following **General Procedure A** and/or **B**, wet flash column chromatography (EtOAc/hexane, 1:9) furnished the title compound **31** \((R_f = 0.62)\) as a yellow oil: IR (ATR, cm\(^{-1}\)) \(\nu_{\text{max}}\) 3057, 2956, 2930, 2870, 2858, 1613, 1490, 1304, 1150, 777, 741, 695, 666, 429; \(^1\)H NMR (300 MHz, CDCl\(_3\)) \(\delta\) 8.01–7.94 (3H, m), 7.50–7.45 (2H, m), 7.41–7.34 (3H, m), 7.17 (1H, ddd, \(J = 10.0, 8.0, 1.8\) Hz), 4.39 (2H, t, \(J = 7.2\) Hz), 1.96 (2H, quint, \(J = 7.3\) Hz), 1.42–1.23 (4H, m), 0.88 (3H, t, \(J = 6.9\) Hz); \(^{13}\)C NMR (75 MHz, CDCl\(_3\)) \(\delta\) 143.5, 140.9, 133.8, 128.7, 127.6, 127.4, 126.0, 121.6, 121.3, 120.7, 109.2, 48.9, 29.6, 29.0, 22.3, 13.9; HRMS (ESI) \(m/z\) [M+H]\(^+\) Calcd for C\(_{18}\)H\(_{21}\)N\(_2\) 265.1699, found 265.1702 (1.1 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 31

$^{13}$C NMR (75 MHz, CDCl$_3$) 31
3-Phenyl-2-n-pentyl-2H-indazole (32)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:9) gave the title compound 32 \((R_f = 0.30)\) as a colorless oil: IR (ATR, cm\(^{-1}\)) \(\nu_{\text{max}}\) 3057, 2955, 2928, 2858, 2870, 1627, 1602, 1497, 1466, 1365, 1273, 1010, 755, 744, 434; \(^1\)H NMR (300 MHz, CDCl\(_3\)) \(\delta\) 7.73 (1H, d, \(J = 8.7\) Hz), 7.59 – 7.46 (6H, m), 7.31 (1H, ddd, \(J = 7.7, 6.6, 1.1\) Hz), 7.06 (1H, ddd, \(J = 7.4, 6.6, 0.8\) Hz), 4.41 (2H, t, \(J = 7.5\) Hz), 1.96 (2H, quint, 7.4 Hz), 1.34–1.17 (4H, m), 0.83 (3H, t, \(J = 6.9\) Hz); \(^{13}\)C NMR (75 MHz, CDCl\(_3\)) \(\delta\) 148.0, 135.8, 130.0, 129.7, 129.0, 128.7, 128.3, 126.2, 121.6, 121.2, 120.2, 117.1, 50.7, 30.5, 28.8, 22.1, 13.8; HRMS (ESI) \(m/z\): [M+H]\(^+\) Calcd for C\(_{18}\)H\(_{21}\)N\(_2\) 265.1699, found 265.1704 (1.9 ppm).
$^1$H NMR (400 MHz, CDCl$_3$) 32

$^{13}$C NMR (100 MHz, CDCl$_3$) 32
3-Iodo-1-n-pentyl-1H-indazole (33)

Following **General Procedure A** and/or **B**, wet flash column chromatography (EtOAc/hexane, 1:19) furnished the title compound 33 ($R_f = 0.50$) as a yellow oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3059, 2955, 2929, 2860, 2858, 1614, 1459, 1319, 1173, 764, 740; $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 7.48 (1H, d, $J = 8.2$ Hz), 7.43 (1H, ddd, $J = 7.7$ Hz, 6.7 Hz, 1.0 Hz), 7.37 (1H, d, $J = 8.5$ Hz), 7.20 (1H, ddd, $J = 8.1$, 6.7, 1.0 Hz), 4.38 (2H, t, $J = 7.3$ Hz), 1.92 (2H, quint, $J = 7.3$ Hz), 1.40–1.26 (4H, m), 0.87 (3H, t, $J = 7.1$ Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 140.1, 128.2, 127.2, 121.7, 121.2, 109.2, 90.6, 49.6, 29.8, 29.0, 22.3, 14.0; HRMS (ESI) $m/z$ [M+H]$^+$ Calcd for C$_{12}$H$_{18}$IN$_2$ 315.0358, found 315.0362 (1.3 ppm).
$^1$H NMR (400 MHz, CDCl$_3$) 33

$^{13}$C NMR (100 MHz, CDCl$_3$) 33
3-Iodo-2-n-pentyl-2H-indazole (34)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:19) furnished the title compound 34 ($R_f = 0.30$) as a yellow crystalline solid: m.p. 58–60 °C; IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3056, 2955, 2930, 1462, 1352, 1036, 757, 741, 435; $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 7.67 (1H, dd, $J = 8.7$, 0.6 Hz), 7.40 (1H, d, $J = 8.4$ Hz), 7.31 (1H, ddd, $J = 8.7$, 6.6, 1.0 Hz), 7.12 (1H, ddd, $J = 8.4$, 6.6, 0.7 Hz), 4.50 (2H, t, $J = 7.4$ Hz), 1.99 (2H, quint, $J = 7.7$ Hz), 1.43–1.31 (4H, m), 0.91 (3H, t, $J = 6.8$ Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 149.4, 127.2, 126.8, 122.5, 120.6, 117.9, 75.1, 53.6, 30.3, 28.7, 22.3, 13.9; HRMS (ESI) $m/z$ [M+H]$^+$ Calcd for $C_{12}H_{16}IN_2$ 315.0358, found 315.0357 (−0.3 ppm).
$^1$H NMR (400 MHz, CDCl$_3$) 34

$^{13}$C NMR (100 MHz, CDCl$_3$) 34
3-Bromo-1-\textit{n}\textendash pentyl-1\textit{H}\textendash indazole (35)

Following **General Procedure A** and/or **B**, wet flash column chromatography (Et\textsubscript{2}O/hexane, 1:19) furnished the title compound 35 ($R_t = 0.33$) as a colorless oil: IR (ATR, cm\textsuperscript{-1}) $\nu_{\text{max}}$ 3061, 2956, 2930, 2871, 2859, 1616, 1494, 1462, 1328, 1175, 765, 739, 428; $^1$H NMR (400 MHz, CDCl\textsubscript{3}) $\delta$ 7.57 (1H, d, $J$ = 8.2 Hz), 7.37 (1H, ddd, $J$ = 8.6, 7.5, 1.0 Hz), 7.33 (1H, d, $J$ = 8.5 Hz), 7.15 (1H, ddd, $J$ = 7.9, 7.9, 1.2 Hz), 4.29 (2H, t, $J$ = 7.2 Hz), 1.88 (2H, quint, $J$ = 7.3 Hz), 1.36–1.21 (4H, m), 0.85 (3H, t, $J$ = 7.0 Hz); $^{13}$C NMR (100 MHz, CDCl\textsubscript{3}) $\delta$ 140.4, 127.1, 123.4, 121.0, 120.1, 119.7, 109.1, 49.2, 29.4, 28.7, 22.1, 13.8; HRMS (ESI) $m/z$ [M+H]$^+$ Calcd for C\textsubscript{12}H\textsubscript{16}\textsubscript{79}BrN\textsubscript{2} 267.0497, found 267.0491 (–2.2 ppm).
\(^1\)H NMR (400 MHz, CDCl\textsubscript{3}) 35

\(^{13}\)C NMR (100 MHz, CDCl\textsubscript{3}) 35
3-Bromo-2-n-pentyl-2H-indazole (36)

Following **General Procedure A** and/or **B**, wet flash column chromatography (Et₂O/hexane, 1:19) furnished the title compound **36** ($R_f = 0.17$) as a colorless oil: IR (ATR, cm⁻¹) $\nu_{\text{max}}$ 3059, 2955, 2930, 2871, 2860, 1627, 1461, 1360, 1044, 758, 741; $^1$H NMR (400 MHz, CDCl₃) $\delta$ 7.67 (1H, d, $J = 8.8$ Hz, H₄), 7.51 (1H, d, $J = 8.4$ Hz, H₇), 7.30 (1H, ddd, $J = 8.4$, 6.6, 0.6 Hz, H₆), 7.12 (1H, t, $J = 7.5$ Hz, H₅), 4.47 (2H, t, $J = 7.4$ Hz, H₁'), 1.98 (2H, quint, $J = 7.3$ Hz, H₂'), 1.43–1.30 (4H, m, H₃'/H₄'), 0.90 (3H, t, $J = 6.8$ Hz, H₅'); $^{13}$C NMR (100 MHz, CDCl₃) $\delta$ 148.4, 126.7, 122.2, 121.8, 119.3, 117.8, 105.6, 51.7, 29.9, 28.7, 22.2, 13.9; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C₁₂H₁₆BrN₂ 267.0497, found 267.0495 (− 0.7 ppm).
$^1$H NMR (400 MHz, CDCl$_3$) 36

$^{13}$C NMR (100 MHz, CDCl$_3$) 36
3-Chloro-1-\(n\)-penty1-1\(H\)-indazole (37)

Following **General Procedure A** and/or **B**, wet flash column chromatography (EtOAc/hexane, 1:9) furnished the title compound 37 \((R_f = 0.57)\) as an colorless oil; IR (ATR, cm\(^{-1}\)) \(\nu_{\text{max}}\) 3062, 2957, 2931, 2872, 2860, 1617, 1466, 1337, 1178, 739, 428; \(^1\)H NMR (400 MHz, CDCl\(_3\)) \(\delta\) 7.64 (1H, dd, \(J = 8.2, 1.7\) Hz), 7.41–7.33 (2H, m), 7.16 (1H, ddd, \(J = 7.9, 6.6, 1.1\) Hz), 4.28 (2H, t, \(J 7.2\) Hz), 1.89 (2H, quint, \(J = 7.3\) Hz), 1.38–1.23 (4H, m), 0.86 (3H, t, \(J = 7.0\) Hz); \(^{13}\)C NMR (100 MHz, CDCl\(_3\)) \(\delta\) 140.6, 132.2, 127.2, 120.9, 120.8, 119.6, 109.2, 49.1, 29.4, 28.8, 22.2, 13.8; HRMS (ESI) \(m/z\) [M+H]\(^+\) Calcd for C\(_{12}\)H\(_{16}\)ClN\(_2\) 223.0997, found 223.1000 (1.3 ppm).
$^1$H NMR (400 MHz, CDCl$_3$) 37

$^{13}$C NMR (100 MHz, CDCl$_3$) 37
3-Chloro-2-n-pentyl-2H-indazole (38)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:9) furnished the title compound 38 ($R_f = 0.43$) as an colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3062, 2957, 2931, 2872, 2860, 1617, 1495, 1466, 1336, 1178, 1005, 766, 739, 428; $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 7.28 (1H, d, $J = 8.8$ Hz), 7.55 (1H, d, $J = 8.4$ Hz), 7.30 (1H, ddd, $J = 8.7$, 6.6, 1.1 Hz), 7.11 (1H, ddd, $J = 8.5$, 6.7, 0.7 Hz), 4.43 (2H, t, $J = 7.2$ Hz), 1.98 (2H, quint, $J = 7.3$ Hz), 1.42–1.28 (4H, m), 0.90 (3H, t, $J = 6.9$ Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 147.8, 126.7, 122.0, 119.0, 118.9, 118.6, 117.8, 50.5, 29.7, 28.7, 22.2, 13.9; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{12}$N$_{16}$ClN$_2$ 223.0997, found 223.0996 (– 0.4 ppm).
$^1$H NMR (400 MHz, CDCl$_3$) 38

$^{13}$C NMR (100 MHz, CDCl$_3$) 38
Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:19) gave the title compound 39 ($R_f = 0.20$) as an amber oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3061, 2957, 2931, 2861, 1525, 1497, 1457, 1390, 1316, 1188, 831, 748, 431; $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 8.29 (1H, dd, $J = 8.2$, 1.0 Hz), 7.58–7.53 (2H, m), 7.51–7.44 (1H, m), 4.49 (2H, t, $J = 7.4$ Hz), 2.01 (2H, quint, $J = 7.3$ Hz), 1.42–1.29 (4H, m), 0.89 (3H, t, $J = 6.9$ Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 147.3, 141.2, 128.2, 125.5, 121.5, 116.8, 110.2, 50.6, 29.4, 28.8, 22.2, 13.9; HRMS (ESI) $m/z$ [M+H]$^+$ Calcd for C$_{12}$H$_{16}$N$_3$O$_2$ 234.1237, found 234.1236 (–0.4 ppm).
$^1$H NMR (400 MHz, CDCl$_3$) 39

$^{13}$C NMR (100 MHz, CDCl$_3$) 39
3-Nitro-2-\textit{n}-pentyl-2\textit{H}-indazole (40)

Following **General Procedure B**, wet flash column chromatography (EtOAc/hexane, 1:19) furnished the title compound 40 ($R_f = 0.30$) as a yellow oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3068, 2958, 2930, 2861, 1494, 1440, 1336, 1287, 1088, 822, 751, 433; $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 8.17 (1H, ddd, $J$ = 8.3, 1.8, 0.9 Hz), 7.82 (1H, app. d, $J$ = 8.4 Hz), 7.51–7.43 (2H, m), 4.94 (2H, t, $J$ = 7.5 Hz), 2.01 (2H, quint, $J$ = 7.5 Hz), 1.42–1.37 (4H, m), 0.91 (3H, t, $J$ = 7.1 Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 146.2, 137.2, 129.5, 128.5, 120.4, 119.0, 119.2, 118.0, 55.4, 30.0, 28.6, 22.2, 13.9; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{12}$H$_{16}$N$_3$O$_2$ 234.1237, found 234.1238 (0.4 ppm).
$^1$H NMR (400 MHz, CDCl$_3$) 40

$^{13}$C NMR (100 MHz, CDCl$_3$) 40
1-n-Pentyl-1H-indazole-3-carbonitrile (41)

Following General Procedure A and/or B, preparative thin layer chromatography (EtOAc/hexane, 1:4) gave the title compound 41 ($R_f = 0.65$) as a colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 2957, 2932, 2861, 2233, 1467, 1350, 770, 744, 429; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 7.85 (1H, d, $J$ = 8.2 Hz), 7.53–7.48 (2H, m), 7.35 (1H, ddd, $J$ = 7.9, 6.4, 1.3 Hz), 4.45 (2H, t, $J$ = 7.2 Hz), 1.97 (2H, quint, $J$ = 7.2 Hz), 1.39–1.26 (4H, m), 0.89 (3H, t, $J$ = 7.1 Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 139.5, 127.6, 125.4, 123.5, 119.7, 117.4, 113.8, 110.1, 50.2, 29.3, 28.8, 22.2, 13.9; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{13}$H$_{18}$N$_3$ 214.1339; found 214.1337 (+ 0.9 ppm).
\(^1\)H NMR (300 MHz, CDCl\(_3\)) 41

\[^{13}\text{C} \text{NMR} (100 \text{ MHz, CDCl}_3) 41\]
1-\textit{n}-Pentyl-1\textit{H}-indazole-3-carboxaldehyde (43)

Following \textbf{General Procedure A} and/or \textbf{B}, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 43 ($R_f = 0.83$) as an amber oil: IR (ATR, cm$^{-1}$) $\nu_{max}$ 2956, 2932, 2859, 1679, 1472, 1139, 1092, 787, 744, 514, 432; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 10.24 (1H, s), 8.30 (1H, ddd, $J = 8.1, 1.0, 1.0$ Hz), 7.48–7.45 (2H, m, ), 7.34 (1H, ddd, $J = 8.0, 5.4, 2.5$ Hz), 4.46 (2H, t, $J = 7.2$ Hz), 1.99 (2H, quint, $J = 7.3$ Hz), 1.44–1.26 (4H, m), 0.89 (3H, t, $J = 6.9$ Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 186.8, 142.8, 140.8, 127.2, 123.9, 122.2, 122.0, 109.5, 49.9, 29.2, 28.8, 22.1, 13.8; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{13}$H$_{17}$N$_2$O 217.1335, found 217.1340 (2.3 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 43

$^{13}$C NMR (75 MHz, CDCl$_3$) 43
1-(1-n-Pentyl-1H-indazol-3-yl)ethan-1-one (45)

Following **General Procedure A** and/or **B**, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 45 ($R_f = 0.55$) as a colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3057, 2956, 2932, 2872, 2860, 1670, 1470, 1172, 1155, 939, 746, 569, 432; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.36 (1H, ddd, $J$ = 8.1, 1.0, 1.0 Hz), 7.46–7.40 (2H, m), 7.30 (1H, ddd, $J$ = 8.0, 5.9, 2.1 Hz), 4.41 (2H, t, $J$ = 7.2 Hz), 2.71 (3H, s), 1.97 (2H, quint, $J$ = 7.3 Hz), 1.44–1.27 (4H, m), 0.89 (3H, t, $J$ = 6.9 Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 194.7, 142.1, 140.7, 126.6, 123.4, 122.9, 122.7, 109.2, 49.6, 29.3, 28.8, 26.7, 22.2, 13.8; HRMS (ESI) m/z: [M+H]$^+$ Calcd for C$_{14}$H$_{19}$N$_2$O 231.1492, found 231.1492 (0.0 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 45

$^{13}$C NMR (75 MHz, CDCl$_3$) 45
**N-Methyl-1-n-pentyl-1H-indazole-3-carboxamide (47)**

Following General Procedure A and/or B, the title compound 47 was isolated upon work-up as an amber oil: IR (ATR, cm⁻¹) νₘₑₓ 3333, 2955, 2931, 2871, 1651, 1539, 1182, 772, 749, 547; ¹H NMR (400 MHz, CDCl₃) δ 8.39 (1H, d, J = 8.2 Hz), 7.41–7.40 (2H, m), 7.30–7.23 (1H, m), 7.02, (1H, d, J = 3.2 Hz), 4.35 (2H, t, J = 7.2 Hz), 3.05 (3H, d, J = 5.0 Hz), 1.93 (2H, quint, J = 7.3 Hz), 1.40–1.25 (4H, m), 0.88 (3H, t, J = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 163.3, 140.7, 137.2, 126.6, 122.9, 122.7, 122.4, 109.1, 49.3, 29.4, 28.8, 25.6, 22.2, 13.9; HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₄H₂₀N₃O 246.1601, found 246.1599 (+ 0.8 ppm).
$^1$H NMR (400 MHz, CDCl$_3$) 47

$^{13}$C NMR (100 MHz, CDCl$_3$) 47
(1-n-Pentyl-1H-indazol-3-yl)(pyrrolidin-1-yl)methanone (49)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 3:7) gave the title compound 49 ($R_f = 0.30$) as a colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3055, 2955, 2931, 2871, 1610, 1479, 1443, 1345, 1183, 1169, 748, 432; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.36 (1H, ddd, $J = 8.2$, 1.0, 1.0 Hz), 7.41–7.37 (2H, m), 7.25–7.20 (1H, m), 4.37 (2H, t, $J = 7.0$ Hz), 4.03 (2H, t, $J = 6.6$ Hz), 3.75 (2H, t, $J = 6.6$ Hz), 2.03–1.87 (6H, m), 1.41–1.22 (4H, m), 0.87 (3H, t, $J = 7.0$ Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 162.3, 139.8, 138.6, 126.2, 124.3, 123.1, 121.8, 108.7, 49.0, 48.8, 46.6, 29.2, 28.7, 26.5, 23.8, 22.1, 13.8; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{17}$H$_{24}$N$_3$O 286.1914, found 286.1910 (– 1.4 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 49

$^{13}$C NMR (75 MHz, CDCl$_3$) 49
7-Methyl-1-n-pentyl-1H-indazole (51)

Following General Procedure A and/or B, wet flash column chromatography (Et₂O/hexane, 1:4) gave the title compound 51 (Rᵣ = 0.40) as a colorless oil: IR (ATR, cm⁻¹) νₑₓₘ₃ 3059, 3033, 2955, 2930, 2861, 1607, 1465, 1409, 1053, 859, 832, 773, 743, 637; ¹H NMR (300 MHz, CDCl₃) δ 7.94 (1H, s), 7.53 (1H, dd, J = 7.9, 0.5 Hz), 7.07 (1H, ddd, J = 6.9, 1.0, 1.0 Hz), 6.99 (1H, dd, J = 7.9, 7.0 Hz), 4.55 (1H, t, J = 7.5 Hz), 2.70 (3H, s), 1.89 (2H, quint, J = 7.4 Hz), 1.42–1.26 (4H, m), 0.89 (3H, t, J = 7.0 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 138.7, 132.9, 128.1, 124.8, 120.5, 119.8, 118.9, 51.3, 31.5, 28.8, 22.3, 19.4, 13.9; HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₃H₁₉N₂ 203.1543, found 203.1541 (−1.0 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 51

$^{13}$C NMR (75 MHz, CDCl$_3$) 51
7-Methyl-2-n-pentyl-2H-indazole (52)

Following **General Procedure A** and/or **B**, wet flash column chromatography (Et$_2$O/hexane, 1:4) gave the title compound **52** ($R_f = 0.27$) as a colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 2955, 2930, 2871, 2859, 1531, 1467, 1152, 1001, 873, 793, 750; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 7.86 (1H, s), 7.49–7.45 (1H, m), 7.14–6.94 (2H, m), 4.40 (2H, t, $J = 7.3$ Hz), 2.63 (3H, s), 2.00 (2H, quint, $J = 7.4$ Hz), 1.43–1.25 (4H, m), 0.89 (3H, t, $J = 6.9$ Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 149.0, 127.4, 124.7, 122.5, 121.7, 121.5, 117.4, 53.7, 30.5, 28.8, 22.2, 17.2, 13.8; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{13}$H$_{19}$N$_2$ 203.1543, found 203.1542 (± 0.5 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) $^{52}$

$^{13}$C NMR (75 MHz, CDCl$_3$) $^{52}$
7-Bromo-1-n-pentyl-1H-indazole (53)

Following General Procedure A and/or B, wet flash column chromatography (Et₂O/hexane, 1:4) gave the title compound 53 (Rᵣ = 0.50) as a colorless oil: IR (ATR, cm⁻¹) νₘₚₙ 3063, 2955, 2930, 2859, 1608, 1556, 1493, 1447, 1313, 1109, 938, 820, 772, 731, 567; ¹H NMR (300 MHz, CDCl₃) δ 7.97 (1H, s), 7.64 (1H, dd, J = 8.0, 0.9 Hz), 7.52 (1H, dd, J = 7.4, 0.9 Hz), 6.94 (1H, dd, J = 8.0, 7.5 Hz), 4.77 (2H, t, J = 7.5 Hz), 1.91 (2H, quint, J = 7.4 Hz), 1.43–1.28 (4H, m), 0.89 (3H, t, J = 6.9 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 136.5, 132.8, 130.9, 126.7, 121.4, 120.4, 102.8, 50.8, 31.3, 28.7, 22.3, 13.9; HRMS (ESI) m/z: [M+H]+ Calcd for C₄₁₂H₄₈BrN₂ 267.0491, found 267.0486 (−1.9 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 53

$^{13}$C NMR (75 MHz, CDCl$_3$) 53
7-Bromo-2-n-pentyl-2H-indazole (54)

Following General Procedure A and/or B, wet flash column chromatography (Et₂O/hexane, 1:4) gave the title compound 54 ($R_f = 0.17$) as a colorless oil: IR (ATR, cm⁻¹) $\nu_{\text{max}}$ 2955, 2930, 2870, 2859, 1622, 1509, 1464, 1376, 1152, 1139, 937, 796, 738; $^1$H NMR (300 MHz, CDCl₃) $\delta$ 7.97 (1H, s), 7.58 (1H, dd, $J = 8.3$, 0.8 Hz), 7.47 (1H, dd, $J = 7.2$, 0.9 Hz), 6.91 (1H, dd, $J = 8.3$, 7.2 Hz), 4.42 (2H, t, $J = 7.4$ Hz), 2.00 (2H, quint, $J = 7.4$ Hz), 1.40–1.24 (4H, m), 0.88 (3H, t, $J = 6.9$ Hz); $^{13}$C NMR (75 MHz, CDCl₃) $\delta$ 147.1, 128.4, 123.7, 122.5, 122.0, 119.5, 110.8, 53.9, 30.3, 28.6, 22.2, 13.7; HRMS (ESI) $m/z$: [M+H]⁺ Calcd for $\text{C}_{12}\text{H}_{16}\text{BrN}_2$ 267.0491, found 267.0488 (−1.1 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 54

$^{13}$C NMR (75 MHz, CDCl$_3$) 54
7-Nitro-1-n-pentyl-1H-indazole (55)

Following **General Procedure B**, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 55 ($R_f = 0.66$) as a yellow oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 2957, 2930, 2860, 1622, 1520, 1374, 1321, 996, 872, 842, 791, 729, 618; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.17 (1H, s), 8.09 (1H, dd, $J = 7.7$, 1.0 Hz), 8.02 (1H, dd, $J = 8.0$, 1.0 Hz), 7.21 (1H, t, $J = 7.8$ Hz), 4.61 (2H, t, $J = 7.5$ Hz), 1.76 (2H, quint, $J = 7.4$ Hz), 1.38–1.18 (4H, m), 0.86 (3H, t, $J = 7.1$ Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 135.4, 134.1, 130.1, 129.0, 127.8, 124.5, 119.5, 53.2, 30.1, 28.6, 22.1, 13.8; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{12}$H$_{16}$N$_3$O$_2$ 234.1237, found 234.1230 ($\pm$ 3.0 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 55

$^{13}$C NMR (75 MHz, CDCl$_3$) 55
7-Nitro-2-\(n\)-pentyl-\(2H\)-indazole (56)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 56 \((R_f = 0.17)\) as a yellow oil: IR (ATR, cm\(^{-1}\)) \(\nu_{\text{max}}\) 3123, 1956, 2931, 2861, 1634, 1512, 1331, 1298, 1151, 992, 818, 740; \(^{1}\)H NMR (300 MHz, CDCl\(_3\)) \(\delta\) 8.33 (1H, dd, \(J = 7.6, 1.0\) Hz), 8.20 (1H, s), 8.05 (1H, dd, \(J = 8.2, 1.0\) Hz), 7.18 (1H, dd, \(J = 8.2, 7.6\) Hz), 4.55 (2H, t, \(J = 7.4\) Hz), 2.07 (2H, quint, \(J = 7.4\) Hz), 1.45–1.29 (4H, m), 0.90 (3H, t, \(J = 6.9\) Hz); \(^{13}\)C NMR (75 MHz, CDCl\(_3\)) \(\delta\) 140.6, 137.6, 128.7, 125.5, 125.0, 124.9, 120.0, 54.5, 30.3, 28.7, 22.2, 13.9; HRMS (ESI) \(m/z\): [M+H]\(^+\) Calcd for C\(_{12}\)H\(_{18}\)N\(_3\)O\(_2\) 234.1237, found 234.1231 (−2.6 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 56

$^{13}$C NMR (75 MHz, CDCl$_3$) 56
Methyl 1-\(n\)-pentyl-1\(H\)-indazole-7-carboxylate (57)

Following General Procedure B, wet flash column chromatography (Et\(_2\)O/hexane, 1:4) gave the title compound 57 (\(R_f = 0.67\)) as a colorless oil: IR (ATR, cm\(^{-1}\)) \(\nu_{\text{max}}\) 2954, 2931, 2860, 1720, 1454, 1435, 1263, 1212, 1136, 1115, 856, 839, 751, 742, 642; \(^1\)H NMR (300 MHz, CDCl\(_3\)) \(\delta\) 8.06 (1H, s), 7.92–7.78 (2H, m), 7.13 (1H, dd, \(J = 8.0, 7.4\) Hz), 4.71 (2H, t, \(J = 7.4\) Hz), 3.97 (3H, s), 1.77 (2H, quint, \(J = 7.4\) Hz), 1.38–1.18 (4H, m), 0.86 (3H, t, \(J = 7.0\) Hz); \(^{13}\)C NMR (75 MHz, CDCl\(_3\)) \(\delta\) 166.8, 136.0, 133.5, 129.9, 126.6, 125.8, 119.4, 115.4, 52.3, 52.2, 29.9, 28.7, 22.2, 13.8; HRMS (ESI) \(m/z\) [M+H]\(^+\) Calcd for C\(_{14}\)H\(_{19}\)N\(_2\)O\(_2\) 247.1441, found 247.1440 (−0.4 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 57

$^{13}$C NMR (75 MHz, CDCl$_3$) 57
Methyl 2-n-pentyl-2H-indazole-7-carboxylate (58)

Following General Procedure A and/or B, wet flash column chromatography (Et₂O/hexane, 1:4) gave the title compound 58 ($R_f = 0.10$) as a colorless oil: IR (ATR, cm⁻¹) $\nu_{\text{max}}$ 3113, 2952, 2932, 2871, 1706, 1277, 1265, 1200, 1136, 1038, 755; $^1$H NMR (300 MHz, CDCl₃) $\delta$ 8.08 (1H, dd, $J = 7.1$, 1.1 Hz), 8.03 (1H, s), 7.88 (1H, dd, $J = 8.3$, 1.1 Hz), 7.12 (1H, dd, $J = 8.3$, 7.1 Hz), 4.49 (2H, t, $J = 4.5$ Hz), 4.01 (3H, s), 2.05 (2H, quint, $J = 7.4$ Hz), 1.44–1.29 (4H, m), 0.90 (3H, t, $J = 6.9$ Hz); $^{13}$C NMR (75 MHz, CDCl₃) $\delta$ 166.5, 145.9, 130.4, 125.9, 123.4, 123.2, 120.4, 119.0, 54.0, 52.0, 30.2, 28.7, 22.1, 13.8; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C₁₄H₁₉N₂O₂ 247.1441, found 247.1440 (−0.4 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 58

$^{13}$C NMR (75 MHz, CDCl$_3$) 58
Methyl 1-\(n\)-pentyl-1\(H\)-indazole-6-carboxylate (59)

Following **General Procedure A** and/or **B**, wet flash column chromatography (Et\(_2\)O/hexane, 1:4) gave the title compound 59 (R\(_f\) = 0.27) as a colorless oil: IR (ATR, cm\(^{-1}\)) \(\nu_{\text{max}}\) 2954, 2932, 2860, 1717, 1434, 1275, 1252, 1234, 1084, 761, 741, 630, 429; \(^1\)H NMR (300 MHz, CDCl\(_3\)) \(\delta\) 8.12 (1H, dd, \(J = 2.0, 1.0\) Hz), 8.03 (1H, d, \(J = 1.0\) Hz), 7.79 (1H, dd, \(J = 8.5, 1.3\) Hz), 7.74 (1H, dd, \(J = 8.5, 1.3\) Hz), 4.42 (2H, t, \(J = 7.2\) Hz), 3.97 (3H, s), 1.94 (2H, quint, \(J = 7.3\) Hz), 1.43–1.24 (4H, m), 0.88 (3H, t, \(J = 6.9\) Hz); \(^{13}\)C NMR (75 MHz, CDCl\(_3\)) \(\delta\) 167.3, 138.8, 132.6, 127.7, 126.4, 120.8, 120.7, 111.4, 52.2, 49.1, 29.5, 28.8, 22.2, 13.8; HRMS (ESI) \(m/z\): [M+H]\(^+\) Calcd for C\(_{14}\)H\(_{19}\)N\(_2\)O\(_2\) 247.1441, found 247.1436 (−2.0 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 59

$^{13}$C NMR (75 MHz, CDCl$_3$) 59
Methyl 2-\textit{n}-pentyl-2\textit{H}-indazole-6-carboxylate (60)

Following General Procedure A and/or B, wet flash column chromatography (Et\textsubscript{2}O/hexane, 1:4) gave the title compound 60 \((R\textsubscript{f} = 0.07)\) as a colorless oil: IR (ATR, cm\textsuperscript{-1}) \(\nu_{max} 2953, 2932, 2871, 1713, 1434, 1326, 1244, 1221, 1083, 747, 436\); \textsuperscript{1}H NMR (300 MHz, CDCl\textsubscript{3}) \(\delta 8.51 (1\text{H, dd, } J = 2.1, 1.0 \text{ Hz}), 7.93 (1\text{H, d, } J = 0.8 \text{ Hz}), 7.71 (1\text{H, dd, } J = 8.8, 1.3 \text{ Hz}), 7.66 (1\text{H, dd, } J = 8.8, 0.9 \text{ Hz}), 4.42 (2\text{H, t, } J = 7.2 \text{ Hz}), 3.94 (3\text{H, s}), 2.02 (2\text{H, quint, } J = 7.3 \text{ Hz}), 1.43–1.25 (4\text{H, m}), 0.89 (3\text{H, t, } J = 7.0 \text{ Hz}); \textsuperscript{13}C NMR (75 MHz, CDCl\textsubscript{3}) \(\delta 167.5, 147.9, 127.5, 123.8, 122.7, 121.13, 121.12, 120.0, 54.1, 52.0, 30.2, 28.6, 22.1, 13.7\); HRMS (ESI) \(m/z \) [M+H]\textsuperscript{+} Calcd for C\textsubscript{14}H\textsubscript{19}N\textsubscript{2}O\textsubscript{2} 247.1441, found 247.1436 (– 2.0 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 60

$^{13}$C NMR (75 MHz, CDCl$_3$) 60
Methyl 1-\textit{n}-pentyl-1\textit{H}-indazole-5-carboxylate (61)

Following \textbf{General Procedure A} and/or \textbf{B}, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound \textbf{61} ($R_f = 0.43$) as an amber oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 2954, 2932, 2871, 1713, 1619, 1435, 1313, 1250, 1178, 1088, 767; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.51 (1H, dd, $J = 1.5$, 0.8 Hz), 8.09 (1H, d, $J = 0.9$ Hz), 8.05 (1H, dd, $J = 8.9$, 1.5 Hz), 7.41 (1H, ddd, $J = 8.9$, 0.8, 0.8 Hz), 4.38 (2H, t, $J = 7.1$ Hz), 3.94 (3H, s), 1.94 (2H, quint, $J = 7.3$ Hz), 1.42–1.23 (4H, m), 0.88 (3H, t, $J = 7.0$ Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 167.3, 141.1, 134.5, 126.9, 124.7, 123.6, 122.7, 108.7, 52.0, 49.1, 29.5, 28.9, 22.2, 13.9; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{14}$H$_{19}$N$_2$O$_2$ 247.1441, found 247.1435 (−2.4 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 61

$^{13}$C NMR (75 MHz, CDCl$_3$) 61
Methyl 2-n-pentyl-2H-indazole-5-carboxylate (62)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 62 ($R_f = 0.23$) as a yellow crystalline solid: m.p. 47–48 °C; IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 2953, 2933, 2871, 1709, 1628, 1435, 1309, 1239, 1146, 1086, 769, 438; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.49 (1H, dd, $J = 1.5$. 0.9 Hz), 8.04 (1H, s), 7.90 (1H, dd, $J = 9.1$. 1.6 Hz), 7.70 (1H, ddd, $J = 9.1$. 0.9, 0.9 Hz), 4.41 (2H, t, $J = 7.2$ Hz), 3.93 (3H, s), 2.02 (2H, quint, $J = 7.3$ Hz), 1.43–1.25 (4H, m), 0.89 (3H, t, $J = 6.9$ Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 167.4, 150.0, 125.5, 124.9, 124.7, 123.5, 121.0, 117.1, 54.0, 51.9, 30.1, 28.6, 22.1, 13.8; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{14}$H$_{19}$N$_2$O$_2$ 247.1441, found 247.1431 (– 4.0 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 62

$^{13}$C NMR (75 MHz, CDCl$_3$) 62
Methyl 1-\(n\)-penty-1\(H\)-indazole-4-carboxylate (63)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 63 \((R_f = 0.50)\) as a pale yellow oil: IR (ATR, \text{cm}^{-1}) \(\nu_{\text{max}} 2953, 2932, 1714, 1698, 1450, 1274, 1167, 1132, 925, 751\); \(^1\)H NMR \((300 \text{ MHz, } \text{CDCl}_3) \delta 8.49 (1\text{H, d, } J = 0.8 \text{ Hz}), 7.91 (1\text{H, dd, } J = 7.2, 0.7 \text{ Hz}), 7.62 (1\text{H, d, } J = 8.4 \text{ Hz}), 7.42 (1\text{H, dd, } J = 8.4, 7.2 \text{ Hz}), 4.41 (2\text{H, t, } J = 7.1 \text{ Hz}), 4.01 (3\text{H, s}), 1.93 (2\text{H, quint, } J = 7.3 \text{ Hz}), 1.41–1.23 (4\text{H, m}), 0.87 (3\text{H, t, } J = 7.0 \text{ Hz}); ^{13}\text{C NMR (75 MHz, } \text{CDCl}_3) \delta 166.8, 139.8, 133.6, 125.3, 124.0, 123.0, 122.4, 113.9, 52.1, 49.1, 29.6, 29.0, 22.3, 13.9\); HRMS (ESI) \(m/z: [M+H]^+\) Calcd for \(\text{C}_{14}\text{H}_{19}\text{N}_2\text{O}_2 247.1441\), found 247.1436 (– 2.0 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 63

$^{13}$C NMR (75 MHz, CDCl$_3$) 63
Methyl 2-n-pentyl-2H-indazole-4-carboxylate (64)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 64 ($R_f = 0.33$) as a colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 2953, 2932, 2871, 2860, 1709, 1435, 1380, 1269, 1202, 1172, 1136, 1047, 785, 756; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.43 (1H, d, $J = 0.7$ Hz), 7.94 (1H, ddd, $J = 8.6$, 0.8, 0.8 Hz), 7.90 (1H, dd, $J = 7.1$, 0.8 Hz), 7.33 (1H, dd, $J = 8.6$, 7.1 Hz), 4.44 (2H, t, $J = 7.2$ Hz), 3.98 (3H, s), 2.04 (2H, quint, $J = 7.3$ Hz), 1.44–1.25 (4H, m), 0.90 (3H, t, $J = 6.9$ Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 166.8, 149.0, 126.0, 124.7, 124.4, 123.2, 122.2, 120.0, 53.9, 51.9, 30.3, 28.7, 22.1, 13.8; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{14}$H$_{19}$N$_2$O$_2$ 247.1441, found 247.1436 (– 2.0 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 64

$^{13}$C NMR (75 MHz, CDCl$_3$) 64
Methyl 1-benzyl-1H-indazole-3-carboxylate (69)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 69 ($R_f = 0.36$) as a yellow oil which solidified upon standing at room temperature: m.p. 79 °C (lit. m.p. 80–82 °C)[14]; IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3032, 2951, 1709, 1478, 1439, 1228, 1160, 1123, 729; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.24 (1H, ddd, $J = 8.0, 1.2, 0.9$ Hz), 7.40–7.19 (8H, m), 5.70 (2H, s), 4.05 (3H, s); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 163.1, 140.5, 135.6, 135.0, 128.8, 128.1, 127.2, 127.0, 124.1, 123.2, 122.2, 110.0, 54.1, 52.0; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{16}$H$_{15}$N$_2$O$_2$ 267.1128, found 267.1121 (– 2.6 ppm). Spectral data were in agreement with literature values [14].
$^1$H NMR (300 MHz, CDCl₃) 69

![H NMR spectrum](image)

$^{13}$C NMR (75 MHz, CDCl₃) 69

![C NMR spectrum](image)
Methyl 2-benzyl-2H-indazole-3-carboxylate (70)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 70 ($R_f = 0.60$) as a colorless oil which solidified upon standing at room temperature: m.p. 74–76 °C; IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3065, 3034, 2954, 1713, 1466, 1278, 1210, 1088, 760, 707; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.02 (1H, d, $J = 8.3$ Hz), 7.82 (1H, dd, $J = 8.5$, 0.9 Hz), 7.38–7.21 (7H, m), 6.11 (2H, s), 3.99 (3H, s); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 160.6, 147.7, 136.4, 128.6, 128.0, 127.8, 126.5, 125.2, 123.7, 123.6, 121.5, 118.4, 56.6, 52.0; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{16}$H$_{13}$N$_2$O$_2$ 267.1128, found 267.1124 (– 1.5 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 70

$^{13}$C NMR (75 MHz, CDCl$_3$) 70
Methyl 1-(2-methylbenzyl)-1H-indazole-3-carboxylate (71)

Following **General Procedure A** and/or **B**, wet flash column chromatography (EtOAc/hexane, 1:9) gave the title compound 71 \((R_f = 0.17)\) as a colorless oil which solidified upon standing at room temperature: m.p. 85–86 °C; IR (ATR, cm\(^{-1}\)) \(\nu_{\text{max}}\) 3013, 2953, 1713, 1479, 1232, 1160, 1125, 738, 431; \(^1\)H NMR (300 MHz, CDCl\(_3\)) \(\delta\) 8.27–8.24 (1H, m), 7.37–7.22 (3H, m), 7.20–7.15 (2H, m), 7.12–7.04 (1H, m), 6.78 (1H, d, \(J = 7.5\) Hz), 5.71 (2H, s), 4.05 (3H, s), 2.35 (3H, s); \(^13\)C NMR (75 MHz, CDCl\(_3\)) \(\delta\) 160.1, 140.9, 135.8, 134.9, 133.6, 130.6, 128.1, 127.5, 127.0, 126.4, 124.1, 123.3, 122.3, 110.1, 52.5, 52.0, 19.3; HRMS (ESI) \(m/z\): \([\text{M}+\text{H}]^+\) Calcd for C\(_{17}\)H\(_{17}\)N\(_2\)O\(_2\) 281.1285, found 281.1283 (– 0.7 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 71

$^{13}$C NMR (75 MHz, CDCl$_3$) 71
Methyl 2-(2-methylbenzyl)-2H-indazole-3-carboxylate (72)

Following **General Procedure B**, wet flash column chromatography (EtOAc/hexane, 1:9) gave the title compound **72** ($R_f = 0.37$) as a colorless crystalline solid: m.p. 87 °C; IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3022, 2952, 1708, 1463, 1279, 1207, 1082, 757, 740, 725, 440; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.05 (1H, ddd, $J = 8.2$, 1.4, 1.1 Hz), 7.82 (1H, ddd, $J = 8.4$, 1.1, 0.8 Hz), 7.37 (1H, ddd, $J = 8.1$, 6.8, 1.3 Hz), 7.31 (1H, ddd, $J = 8.3$, 6.7, 1.3 Hz), 7.22–7.12 (2H, m), 7.03 (1H, dd, $J = 7.4$, 1.7 Hz), 6.55 (1H, d, $J = 7.7$ Hz), 6.13 (2H, s), 3.97 (3H, s), 2.45 (3H, s); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 160.6, 147.7, 135.3, 135.1, 130.2, 127.6, 126.4, 126.3, 126.2, 125.2, 124.1, 123.6, 121.5, 118.5, 54.5, 52.0, 19.3; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for $C_{17}H_{17}N_2O_2$ 281.1285, found 281.1284 (– 0.4 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 72

$^{13}$C NMR (75 MHz, CDCl$_3$) 72
Methyl 1-(cyclohexylmethyl)-1H-indazole-3-carboxylate (73)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 73 ($R_t = 0.47$) as a yellow oil: IR (ATR, cm$^{-1}$) $\nu_{\max}$ 2924, 2851, 1727, 1709, 1477, 1440, 1223, 1159, 1119, 790, 771, 750, 741; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.23 (1H, ddd, $J$ = 8.2, 0.9, 0.8 Hz), 7.48–7.39 (2H, m), 7.30 (1H, ddd, $J$ = 7.9, 6.2, 1.5 Hz), 4.28 (2H, d, $J$ = 7.3 Hz), 4.04 (3H, s), 2.16–2.01 (1H, m), 1.72–1.55 (5H, m), 1.28–0.98 (5H, m); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 163.1, 141.1, 134.4, 126.6, 123.6, 122.9, 122.1, 109.8, 55.9, 51.9, 38.7, 30.8, 26.1, 25.5; HRMS (ESI) m/z: [M+Na]$^+$ Calcd for C$_{16}$H$_{20}$N$_2$O$_2$Na 295.1417, found 295.1416 (−0.3 ppm). Spectral data were in agreement with literature values [12].
$^1$H NMR (300 MHz, CDCl$_3$) 73

$^{13}$C NMR (75 MHz, CDCl$_3$) 73
Methyl 2-(cyclohexylmethyl)-2H-indazole-3-carboxylate (74)

Following General Procedure B, wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound 74 ($R_f = 0.67$) as a yellow oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 2924, 2851, 1711, 1463, 1277, 1205, 1072, 779, 758, 739, 431; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.02 (1H, ddd, $J$ = 8.3, 1.2, 1.0 Hz), 7.79 (1H, ddd, $J$ = 8.4, 1.1, 1.0 Hz), 7.34 (1H, ddd, $J$ = 8.0, 6.7, 1.2 Hz), 7.27 (1H, ddd, $J$ = 8.3, 6.7, 1.2 Hz), 4.77 (2H, d, $J$ = 7.3 Hz), 4.03 (3H, s), 2.13–2.01 (1H, m), 1.71–1.56 (5H, m), 1.32–1.04 (5H, m); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 160.8, 147.2, 126.2, 124.9, 123.8, 123.4, 121.4, 118.2, 59.2, 51.9, 39.5, 30.5, 26.3, 25.7; HRMS (ESI) $m/z$ [M+H]$^+$ Calcd for C$_{16}$H$_{21}$N$_2$O$_2$ 273.1598, found 273.1596 (± 0.7 ppm). Spectral data were in agreement with literature values [12].
$^1$H NMR (300 MHz, CDCl$_3$) 74

$^{13}$C NMR (75 MHz, CDCl$_3$) 74
Methyl 1-(pentan-2-yl)-1H-indazole-3-carboxylate (75)

Following **General Procedure A** and/or **B**, wet flash column chromatography (EtOAc/hexane, 1:9) gave the title compound 75 ($R_f = 0.27$) as a colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3064, 2957, 2935, 2874, 1731, 1709, 1475, 1191, 1168, 1125, 752, 649, 433; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.24 (1H, d, $J = 8.2$ Hz), 7.51 (1H, d, $J = 8.5$ Hz), 7.41 (1H, ddd, $J = 8.0, 6.8, 1.1$ Hz), 7.30 (1H, ddd, $J = 7.8, 6.8, 0.8$ Hz), 4.78 (1H, tq, $J = 8.6, 6.7$ Hz), 4.40 (3H, s), 2.27–2.11 (1H, m), 1.95–1.82 (1H, m), 1.64 (3H, d, $J = 6.9$ Hz), 1.34–1.02 (2H, m), 0.87 (3H, t, $J = 7.3$ Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 163.2, 140.2, 134.4, 126.4, 123.8, 122.9, 122.2, 109.7, 56.0, 51.8, 38.3, 20.5, 19.6, 13.6; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{14}$H$_{19}$N$_2$O$_2$ 247.1441, found 247.1453 (4.9 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 75

\[ \text{Chemical Structure} \]

$^{13}$C NMR (75 MHz, CDCl$_3$) 75

\[ \text{Chemical Structure} \]
Methyl 2-(pentan-2-yl)-2H-indazole-3-carboxylate (76)

Following **General Procedure A** and/or **B**, wet flash column chromatography (EtOAc/hexane, 1:9) gave the title compound 76 ($R_f = 0.50$) as a colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 2957, 2934, 2873, 1709, 1455, 1270, 1202, 1079, 759; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.02 (1H, ddd, $J = 8.4$, 1.3, 1.1 Hz), 7.82 (1H, ddd, $J = 8.5$, 1.2, 1.0 Hz), 7.33 (1H, ddd, $J = 8.2$, 6.7, 1.3 Hz), 7.26 (1H, ddd, $J = 7.9$, 6.7, 1.1 Hz), 5.91 (1H, tq, $J = 8.5$, 6.6 Hz), 4.02 (3H, s), 2.24–2.07 (1H, m), 1.90–1.80 (1H, m), 1.62 (3H, d, $J = 6.6$ Hz), 1.36–1.01 (2H, m), 0.88 (3H, t, $J = 7.3$ Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 160.9, 147.4, 125.9, 124.7, 123.6, 123.2, 121.4, 118.3, 57.3, 51.7, 39.2, 21.5, 19.3, 13.7; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{14}$H$_{19}$N$_2$O$_2$ 247.1441, found 247.1440 (–0.4 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 76

$^1$H NMR spectrum showing peaks at various ppm values.

$^{13}$C NMR (75 MHz, CDCl$_3$) 76

$^{13}$C NMR spectrum showing peaks at various ppm values.
Methyl 1-(pentan-3-yl)-1H-indazole-3-carboxylate (77)

Following General Procedure A and/or B, wet flash column chromatography (EtOAc/hexane, 1:9) gave the title compound 77 ($R_f = 0.27$) as a colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 3058, 2967, 2934, 2877, 1710, 1475, 1439, 1407, 1244, 1191, 1165, 1125, 1084, 1008, 749, 432; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.24 (1H, ddd, $J = 8.2$, 1.0, 1.0 Hz), 7.51 (1H, d, $J = 8.5$ Hz), 7.41 (1H, ddd, $J = 8.0$, 6.8, 1.2 Hz), 7.30 (1H, ddd, $J = 7.9$, 6.8, 0.9 Hz), 4.41 (1H, sept., $J = 4.8$ Hz), 4.04 (3H, s), 2.27–2.12 (2H, m), 2.04–1.90 (2H, m), 0.74 (6H, t, $J = 7.4$ Hz); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 163.4, 141.5, 134.7, 126.5, 123.7, 122.9, 122.3, 109.8, 64.4, 52.0, 28.0, 11.0; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{14}$H$_{19}$N$_2$O$_2$ 247.1441, found 247.1444 (1.2 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 77

$^{13}$C NMR (75 MHz, CDCl$_3$) 77
Methyl 2-(pentan-3-yl)-2H-indazole-3-carboxylate (78)

Following **General Procedure B**, wet flash column chromatography (EtOAc/hexane, 1:9) gave the title compound **78** ($R_f = 0.50$) as a colorless oil: IR (ATR, cm$^{-1}$) $\nu_{\text{max}}$ 2967, 2929, 2876, 1712, 1455, 1361, 1267, 1202, 1080, 756, 743, 439; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 8.04 (1H, ddd, $J = 8.3$, 1.2, 1.0 Hz), 7.82 (1H, ddd, $J = 8.5$, 1.1, 0.9 Hz), 7.35 (1H, ddd, $J = 8.0$, 6.7, 1.3 Hz), 7.28 (1H, ddd, $J = 7.8$, 6.7, 1.1 Hz), 5.73–5.63 (1H, m), 4.03 (3H, s), 2.23–2.08 (2H, m), 2.03–1.89 (2H, m), 0.75 (6H, t, $J = 7.4$ Hz); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 161.1, 177.7, 126.0, 125.0, 124.8, 123.0, 121.6, 118.3, 64.8, 51.8, 28.8, 10.5; HRMS (ESI) $m/z$: [M+H]$^+$ Calcd for C$_{14}$H$_{19}$N$_2$O$_2$ 247.1441, found 247.1444 (1.2 ppm).
$^1$H NMR (300 MHz, CDCl$_3$) 78

$^{13}$C NMR (75 MHz, CDCl$_3$) 78
Synthesis of Tosylates

General Procedure (C):

Following a previously reported method [15], to a glass mortar was added freshly ground KOH (5 equiv.) and alkyl alcohol (1 equiv). The mixture was vigorously ground for 5 min in a glass mortar and pestle (exposed to air) at room temperature. The resulting paste was then mixed with K₂CO₃ (3.6 equiv), TsCl (1.5 equiv), and ground for a further 3 min at room temperature. The reaction mixture was then treated with freshly ground KOH (5 equiv) and three drops of t-BuOH and ground for a further 2 min. The crude paste was then extracted with Et₂O and the resulting organic phase dried under reduced pressure to afford the crude tosylate. When required, further purification of the crude material using recrystallization or wet flash column chromatography gave the desired tosylate.

n-Pentyl 4-methylbenzenesulfonate

Following General Procedure C (employing n-pentanol as the alcohol), wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound ($R_f = 0.67$) as a colorless oil (885 mg, 73%): IR (ATR, cm⁻¹) $\nu_{\text{max}}$ 2958, 2932, 2872, 1598, 1356, 1188, 1174, 1097, 957, 910, 813, 662, 553; $^1$H NMR (300 MHz, CDCl₃) δ 7.79 (2H, ddd, $J = 8.3, 1.9, 1.9$ Hz), 7.34 (2H, dd, $J = 8.5, 0.6$ Hz), 4.02 (2H, t, $J = 6.5$ Hz), 2.45 (3H, s), 1.64 (2H, quint, $J = 6.9$ Hz), 1.36–1.19 (4H, m), 0.85 (3H, t, $J = 7.1$ Hz); $^{13}$C NMR (75 MHz, CDCl₃) δ 144.6, 133.3, 129.8, 127.9, 70.7, 28.5, 27.4, 22.0, 21.6, 13.8; HRMS (ESI) $m/z$: [M+Na]$^+$ Calcd for C₁₂H₁₈O₃Sn 265.0869, found 265.0875 (2.3 ppm)
**$^1$H NMR (300 MHz, CDCl$_3$)**

![$^1$H NMR spectrum](image)

**$^{13}$C NMR (75 MHz, CDCl$_3$)**

![$^{13}$C NMR spectrum](image)
Benzyl 4-methylbenzenesulfonate

Following General Procedure C (employing benzyl alcohol as the alcohol), recrystallization from Et₂O/hexane (1:3) gave the title compound as colorless needles (1.471 g, 56%): m.p. 56–57 °C [Et₂O/hexane] (lit. m.p. 57–58 °C [Et₂O]) [16]; IR (ATR, cm⁻¹) νmax 3033, 2976, 1596, 1455, 1345, 1167, 908, 660, 553; ¹H NMR (300 MHz, CDCl₃) δ 7.79 (2H, ddd, J = 8.3, 1.7, 1.7 Hz), 7.34–7.29 (5H, m), 7.27–7.21 (2H, m), 5.05 (2H, s), 2.44 (3H, s); ¹³C NMR (75 MHz, CDCl₃) δ 144.8, 133.3, 129.8, 129.0, 128.7, 128.5, 128.0, 71.9, 21.6; HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₄H₁₄O₃SNa 285.0556, found 285.0551 (−1.8 ppm). Spectral data were in agreement with literature values [16].
$^1$H NMR (300 MHz, CDCl$_3$)

\[
\begin{align*}
\text{Chemical Shifts:} & \\
& 7.97, 7.4, 3.31, 3.3, 3.29, 3.27, 2.7, 2.35, 2.4, 2.05, 5.15
\end{align*}
\]

$^{13}$C NMR (75 MHz, CDCl$_3$) X116902

\[
\begin{align*}
\text{Chemical Shifts:} & \\
& 144.8, 132.8, 129.6, 128.6, 128.0, 77.5, 77.6, 71.9, 21.6
\end{align*}
\]
Cyclohexylmethyl 4-methylbenzenesulfonate

Following General Procedure C (employing cyclohexylmethanol as the alcohol), wet flash column chromatography (EtOAc/hexane, 1:4) gave the title compound ($R_f = 0.67$) as a colorless oil (1.224 g, 46%): IR (ATR, cm$^{-1}$) $\nu_{\max}$ 2925, 2853, 1599, 1358, 1173, 1098, 971, 812, 664, 553; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 7.78 (2H, ddd, $J = 8.4$, 1.8, 1.8 Hz), 7.34 (2H, d, $J = 8.0$ Hz), 3.81 (2H, d, $J = 6.1$ Hz), 2.45 (3H, s), 1.70–1.59 (6H, m), 1.27–1.04 (3H, m), 0.95–0.84 (2H, m); $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ 144.6, 133.2, 129.8, 127.9, 75.4, 37.2, 29.1, 26.1, 25.4, 21.6; HRMS (ESI) $m/z$: [M+Na]$^+$ Calcd for C$_{14}$H$_{20}$O$_3$SNa 291.1025, found 291.1025 (0.0 ppm). Spectral data were in agreement with literature values [17].
Pentan-2-yl 4-methylbenzenesulfonate

Following General Procedure C (employing pentan-2-ol as the alcohol), the title compound as obtained as a colorless oil (816 mg, 30%): IR (ATR, cm\(^{-1}\)) \(\nu_{\text{max}}\) 2961, 2936, 2875, 1599, 1350, 1188, 1174, 1094, 894, 815, 774, 662, 575, 554; \(^1\)H NMR (300 MHz, CDCl\(_3\)) \(\delta\) 7.79 (2H, d, \(J = 8.2\) Hz), 7.34–7.28 (2H, m), 4.63 (1H, appsext, \(J = 6.3\) Hz), 2.44 (3H, s), 1.67–1.39 (2H, m), 1.36–1.13 (5H, m), 0.82 (3H, t, \(J = 7.3\) Hz); \(^{13}\)C NMR (75 MHz, CDCl\(_3\)) \(\delta\) 144.3, 134.6, 129.6, 127.6, 80.3, 38.5, 21.5, 20.7, 18.1, 13.5; HRMS (ESI) \(m/z\): [M+Na]\(^+\) Calcd for C\(_{12}\)H\(_{16}\)O\(_3\)SNa 265.0869, found 265.0867 (−0.8 ppm). Spectral data were in agreement with literature values [18].
$^1$H NMR (300 MHz, CDCl$_3$)

$^{13}$C NMR (75 MHz, CDCl$_3$)
Regioisomeric distribution (N-1:N-2) determination; Crude $^1$H NMR spectra

Table 1, Entry 3

$^1$H NMR (400 MHz, CDCl$_3$)
Table 1, Entry 18

\[
\text{N} \quad \text{N}
\]

1.1 equiv. NaH,
1.2 equiv. \( n \)-pentyl bromide
THF, N\(_2\), 0 °C \( \rightarrow \) 50 °C,
24 h

\[
\begin{align*}
\text{9} & \quad \text{10} \quad \text{11}
\end{align*}
\]

\( ^1 \text{H NMR} \ (400 \text{ MHz, CDCl}_3) \)
Scheme 1

\[
\begin{align*}
\text{DBAD, PPh}_3, \\
\text{n-pentanol} \\
\text{THF, N}_2, 0 \, \text{°C} \rightarrow \text{rt,} \\
2 \, \text{h}
\end{align*}
\]

\[
\begin{align*}
9 & \xrightarrow{\text{DBAD, PPh}_3, \\
n-pentanol} \text{10} + \text{11}
\end{align*}
\]

$^1$H NMR (300 MHz, CDCl$_3$)
Table 2, Entry 1 (Conditions A)

1H NMR (400 MHz, CDCl3)
Table 2, Entry 1 (Conditions B)

\[ \text{12} \xrightarrow{1.5 \text{ equiv. } \text{C}_3\text{CO}_3, 1.2 \text{ equiv. } n\text{-pentyl bromide}} \text{DMF, rt, 16 h} \xrightarrow{} \text{25} + \text{26} \]

\(^1\text{H NMR (400 MHz, CDCl}_3\)
Table 2, Entry 2 (Conditions A)

\[ \text{1.1 equiv. NaH, 1.2 equiv. n-pentyl bromide} \]
\[ \text{THF, N}_2, 0 \degree \text{C} \rightarrow 50 \degree \text{C}, 24 \text{ h} \]

\[ \begin{align*}
13 & \quad + \quad 27 \\
& \quad + \quad 28
\end{align*} \]

\[ ^1H \text{ NMR (400 MHz, CDCl}_3) \]
Table 2, Entry 2 (Conditions B)

1H NMR (400 MHz, CDCl₃)
Table 2, Entry 3 (Conditions A)

\[
\text{1.1 equiv. NaH, 1.2 equiv. \text{-}pentyl bromide}
\]

\[
\text{THF, N}_2, 0 \degree \text{C} \rightarrow 50 \degree \text{C}, 24 \text{ h}
\]

\[
14 \rightarrow 29 + 30
\]

\[1^1\text{H NMR (400 MHz, CDCl}_3\]
Table 2, Entry 3 (Conditions B)

1H NMR (400 MHz, CDCl₃)
Table 2, Entry 4 (Conditions A)

\[
\text{1H NMR (300 MHz, CDCl}_3)\]

\[
1.1 \text{ equiv. NaH,} \\
1.2 \text{ equiv. } n\text{-pentyl bromide} \\
\text{THF, N}_2, 0^\circ \text{C} \rightarrow 50^\circ \text{C,} \\
24 \text{ h}
\]
Table 2, Entry 4 (Conditions B)

\[
\text{1H NMR (400 MHz, CDCl}_3\text{)}
\]
Table 2, Entry 5 (Conditions A)

1H NMR (300 MHz, CDCl$_3$)
Table 2, Entry 5 (Conditions B)

\[ \text{1.5 equiv. Cs}_2\text{CO}_3, \text{1.2 equiv. } n\text{-pentyl bromide, DMF, rt, 16 h} \]

\[ \begin{align*}
\text{16} & \rightarrow \\
& \text{NMR (400 MHz, CDCl}_3\text{)}
\end{align*} \]

\[ \begin{align*}
\text{1H NMR (400 MHz, CDCl}_3\text{)}
\end{align*} \]
Table 2, Entry 6 (Conditions A)

\[
\begin{align*}
\text{1.1 equiv. NaH,} \\
\text{1.2 equiv. n-pentyl bromide} \\
\text{THF, N}_2, \text{0 °C} & \rightarrow \text{50 °C,} \\
\text{24 h}
\end{align*}
\]

\[
\begin{align*}
17 & \quad & \text{Br} \\
\text{N} & \quad & \text{1} \\
\\text{N} & \quad & \text{35} + \text{36}
\end{align*}
\]

\[\text{^1H NMR (400 MHz, CDCl}_3\text{)}\]

\[
\begin{align*}
\text{7.62} & \quad & \text{7.61} \\
\text{7.60} & \quad & \text{7.59} \\
\text{7.42} & \quad & \text{7.41} \\
\text{7.40} & \quad & \text{7.39} \\
\text{7.38} & \quad & \text{7.37} \\
\text{7.36} & \quad & \text{7.35} \\
\text{4.33} & \quad & \text{4.32} \\
\text{4.32} & \quad & \text{4.31} \\
\text{1.29} & \quad & \text{1.28} \\
\text{0.86} & \quad & \text{0.85}
\end{align*}
\]
Table 2, Entry 6 (Conditions B)

![Reaction Scheme](image)

\[ \text{1.5 equiv. } \text{Cs}_2\text{CO}_3, \quad \text{1.2 equiv. } n\text{-pentyl bromide} \]

DMF, rt, 16 h

\[^1\text{H NMR (400 MHz, CDCl}_3\text{)}\]

![NMR Spectrum](image)
Table 2, Entry 7 (Conditions A)

\[
\begin{align*}
\text{1.1 equiv. NaH,} \\
\text{1.2 equiv. n-pentyl bromide} \\
\text{THF, N}_2, \text{0 °C} \rightarrow \text{50 °C,} \\
\text{24 h}
\end{align*}
\]

\[
\begin{align*}
\text{1H NMR (300 MHz, CDCl}_3\text{)}
\end{align*}
\]
Table 2, Entry 7 (Conditions B)

\[
\begin{align*}
\text{18} & \quad \text{1.5 equiv. Cs}_2\text{CO}_3 \quad \text{1.2 equiv. } n\text{-pentyl bromide} \\
& \quad \text{DMF, rt, 16 h} \\
\rightarrow & \\
\text{37} & \quad + \\
\text{38} & 
\end{align*}
\]

\(^1\text{H NMR (400 MHz, CDCl}_3\text{)}\)
Table 2, Entry 8 (Conditions A)

\[
\begin{align*}
\text{1 equiv. } \text{NaH,} & \quad 1.2 \text{ equiv. } n\text{-pentyl bromide} \\
\text{THF, } N_2, \text{ 0 °C } & \rightarrow 50 \text{ °C,} \\
\text{24 h} & 
\end{align*}
\]

\(^1\)H NMR (400 MHz, CDCl\textsubscript{3})

![1H NMR spectrum](image_url)
Table 2, Entry 8 (Conditions B)

\[
\begin{align*}
\text{1H NMR (400 MHz, CDCl}_3) \\
\end{align*}
\]
Table 2, Entry 9 (Conditions A)

\[
\ce{\text{N} \overset{20}{\text{H}} \text{N} \overset{41}{\text{N}}} \xrightarrow{1.1 \text{ equiv. NaH, 1.2 equiv. } \text{n-pentyl bromide}} \ce{\text{N} \overset{41}{\text{N}} + \text{N} \overset{42}{\text{N}}} \]
\]

\[\text{THF, N}_2, \ 0 \ ^\circ C \rightarrow 50 \ ^\circ C, \ 24 \ h\]

\[^1\text{H NMR (400 MHz, CDCl}_3\text{)}\]

\[\text{ppm}\]

\[\text{9 8 7 6 5 4 3 2 1 0}\]
Table 2, Entry 9 (Conditions B)

\[
\begin{align*}
\text{N} & \quad \xrightarrow{1.5 \text{ equiv. } \text{Cs}_2\text{CO}_3,} \quad \xrightarrow{1.2 \text{ equiv. } n\text{-pentyl bromide}} \\
\text{N} & \quad \xrightarrow{\text{DMF, rt, 16 h}} \\
\end{align*}
\]

\[\text{1H NMR (400 MHz, CDCl}_3\text{)}\]
Table 2, Entry 10 (Conditions A)

\[
\begin{align*}
\text{H NMR (400 MHz, CDCl}_3) \\
\end{align*}
\]

\[\text{1H NMR (400 MHz, CDCl}_3)\]
**Table 2, Entry 10 (Conditions B)**

\[ \text{1H NMR (400 MHz, CDCl}_3) \]

\( \text{H NMR (400 MHz, CDCl}_3) \)
Table 2, Entry 11 (Conditions A)

\[
\begin{align*}
\text{22} & \quad \xrightarrow{1.1 \text{ equiv. NaH,} \quad \text{1.2 equiv. } n\text{-pentyl bromide}} \quad \text{45} + \text{46} \\
\text{THF, N}_2, 0 ^\circ \text{C} \rightarrow 50 ^\circ \text{C}, \quad 24 \text{ h}
\end{align*}
\]

\(^1\)H NMR (300 MHz, CDCl\(_3\))

![NMR Spectrum Image]
Table 2, Entry 11 (Conditions B)

\[
\begin{align*}
\text{22} & \xrightarrow{1.5 \text{ equiv. } \text{Cs}_2\text{CO}_3, \\ 1.2 \text{ equiv. } n-\text{pentyl bromide}} \quad \text{DMF, rt, 16 h} \quad \text{45} + \text{46}
\end{align*}
\]

\(^1\)H NMR (300 MHz, CDCl\textsubscript{3})

[Chemical structure and NMR spectrum image]
Table 2, Entry 12 (Conditions A)

\[ \text{1H NMR (400 MHz, CDCl}_3) \]

\[
\begin{align*}
&1.1 \text{ equiv. NaH,} \\
&1.2 \text{ equiv. } n\text{-pentyl bromide} \\
&\text{THF, N}_2, 0^\circ \text{C} \rightarrow 50^\circ \text{C}, \\
&24 \text{ h}
\end{align*}
\]
Table 2, Entry 12 (Conditions B)

\[
\text{O} \quad \overset{1.5 \text{ equiv. Cs}_2\text{CO}_3, 1.2 \text{ equiv. } n\text{-pentyl bromide}}{\text{DMF, rt, 16 h}} \quad \text{O} \\
\text{\text{N}} \quad \text{N} \\
\text{H} \quad \text{H} \\
23 \quad 47 \quad 48
\]

\(^1\text{H NMR (400 MHz, CDCl}_3\text{)}\)
Table 2, Entry 13 (Conditions A)

\[
\begin{align*}
\text{24} & \xrightarrow{1.1 \text{ equiv. NaH,}} \xrightarrow{1.2 \text{ equiv. } n\text{-pentyl bromide}} \\
& \quad \text{THF, } N_2, 0^\circ \text{C } \rightarrow 50^\circ \text{C, } \\
& \quad 24 \text{ h}
\end{align*}
\]

\[\text{49} + \text{50}\]

\(^1\text{H NMR (300 MHz, CDCl}_3\text{)}\]
Table 2, Entry 13 (Conditions B)

\[
\begin{align*}
\text{24} & \xrightarrow{1.5 \text{ equiv. } \text{Cs}_2\text{CO}_3,} \quad \text{1.2 equiv. } n\text{-pentyl bromide} \\
& \quad \text{DMF, rt, 16 h} \\
\end{align*}
\]

\[
\begin{align*}
\text{49} & + \quad \text{50}
\end{align*}
\]

\(^1\text{H NMR (300 MHz, CDCl}_3\text{)}\)
Table 3, Entry 1

\[
\begin{align*}
\text{O} & \quad \text{O} \\
\text{N} & \quad \text{N} \\
\text{H} & \quad \text{H} \\
9 & \quad \text{1.5 equiv. } \text{Cs}_{2}\text{CO}_{3}, \text{1.2 equiv. } \text{n-pentyl bromide} \quad \text{THF, rt, 16 h} \quad 10 + 11
\end{align*}
\]

\(^1\text{H NMR (300 MHz, CDCl}_3\text{)}\)
Table 3, Entry 2

\[
\begin{align*}
\text{O} & \quad \text{1.5 equiv. Cs$_2$CO$_3$,} \\
\text{N} & \quad \text{1.2 equiv. } n\text{-pentyl bromide} \\
\text{THF, 50 °C, 24 h} & \\
\end{align*}
\]

\[
\begin{align*}
9 & \quad \to \quad 10 + 11 \\
\end{align*}
\]

$^1$H NMR (300 MHz, CDCl$_3$)
Table 3, Entry 3

1.1 equiv. NaH, 1.2 equiv. n-pentyl bromide
DMF, N₂, rt, 16 h

1H NMR (300 MHz, CDCl₃)
Table 3, Entry 4

\[
\begin{array}{c}
\text{O} \\
\text{H}
\end{array}
\begin{array}{c}
\text{N} \\
\text{H}
\end{array}
\xrightarrow{1.1 \text{ equiv. NaH,} \\ 1.2 \text{ equiv. } n\text{-pentyl bromide}}
\begin{array}{c}
\text{O}' \\
\text{N} \\
\text{H}
\end{array}
\begin{array}{c}
\text{C} \\
\text{H}
\end{array}
+ 
\begin{array}{c}
\text{O}' \\
\text{N} \\
\text{H}
\end{array}
\begin{array}{c}
\text{C} \\
\text{H}
\end{array}

\text{DMF, N}_2, 50 ^\circ \text{C, 24 h}
\]

\(^1\text{H NMR (300 MHz, CDCl}_3\)
Table 3, Entry 5

\[
\text{O} \xrightarrow{\text{1.1 equiv. LiH,}} \text{O}
\]
\[
\begin{align*}
\text{1.2 equiv. n-pentyl bromide} \quad \text{THF, N}_2, 0 \, ^\circ \text{C} \to 50 \, ^\circ \text{C}, \\
24 \, \text{h}
\end{align*}
\]

\[
\begin{align*}
\text{9} & \quad \text{10} \\
& + \quad \text{11}
\end{align*}
\]

\[
^1\text{H NMR (300 MHz, CDCl}_3\text{)}
\]

\[
\begin{align*}
\text{ppm} & \quad 4.9 \\
\text{ppm} & \quad 3.4 \quad 3.6
\end{align*}
\]
Table 3, Entry 6

\[
\begin{align*}
\text{1.1 equiv. KH, 1.2 equiv. } n\text{-pentyl bromide} \\
\text{THF, } N_2, 0 \degree C \rightarrow 50 \degree C, 24 \text{ h}
\end{align*}
\]

\[\text{H NMR (300 MHz, CDCl}_3\text{)}\]

\[\text{1H NMR (300 MHz, CDCl}_3\text{)}\]
Table 3, Entry 7

\[
\text{N} \xrightarrow{1.1 \text{ equiv. NaHMDS,}} \xrightarrow{1.2 \text{ equiv. } n\text{-pentyl bromide}} \text{N}
\]

THF, N\text{\textsubscript{2}}, 0 \degree \text{C} \rightarrow 50 \degree \text{C}, 24 \text{ h}

\[
\begin{align*}
\text{1H NMR (300 MHz, CDCl\textsubscript{3})}
\end{align*}
\]
Table 3, Entry 8

\[
\begin{align*}
\text{O} & \quad \text{1.1 equiv. NaH}_{2}, \\
\text{N} & \quad 1.2 \text{ equiv. } n\text{-pentyl bromide} \\
\text{H} & \quad \text{THF, N}_2, 0 \text{ °C } \rightarrow 50 \text{ °C}, \\
\text{N} & \quad 24 \text{ h}
\end{align*}
\]

\[
\begin{align*}
\text{9} & \quad \text{10} \\
+ & \quad \text{11}
\end{align*}
\]

\[\text{H NMR (300 MHz, CDCl}_3\text{)}\]

\[
\begin{align*}
\text{4.9 ppm}
\end{align*}
\]
Table 3, Entry 9

\[
\begin{align*}
\text{9} & \xrightarrow{1.1 \text{ equiv. } \text{LDA},} \text{10} \quad \text{1.2 equiv. } n\text{-pentyl bromide} \\
& \quad \text{THF, } \text{N}_2, 0 \text{ °C } \rightarrow 50 \text{ °C,} \\
& \quad 24 \text{ h} \\
\end{align*}
\]

\[^1\text{H NMR (300 MHz, CDCl}_3\text{)}]

\[
\begin{align*}
& \quad 4.95 \quad 4.90 \quad \text{ppm} \\
& \quad 9 \quad 8 \quad 7 \quad 6 \quad 5 \quad 4 \quad 3 \quad 2 \quad 1 \quad 0 \quad \text{ppm} \\
\end{align*}
\]
Table 4, Entry 1 (Conditions A)

1H NMR (300 MHz, CDCl₃)
Table 4, Entry 1 (Conditions B)

\[
\begin{align*}
&\text{1.5 equiv. Cs}_2\text{CO}_3, \\
&1.2 \text{ equiv. } n\text{-pentyl bromide} \\
&\text{DMF, rt, 16 h} \\
\end{align*}
\]

\[\text{51} \quad + \quad \text{52} \]

$^1$H NMR (300 MHz, CDCl$_3$)
Table 4, Entry 2 (Conditions A)

\[ \text{Br} \quad \text{H} \quad \text{N} \]

1.1 equiv. NaH, 1.2 equiv. n-pentyl bromide
THF, \( N_2 \), 0 \(^\circ\)C → 50 \(^\circ\)C, 24 h

53 + 54

\(^1\)H NMR (300 MHz, CDCl\(_3\))
Table 4, Entry 2 (Conditions B)

\[
\text{Br} \quad \longrightarrow \quad \text{N} \quad \text{Br}
\]

1.5 equiv. Cs₂CO₃
1.2 equiv. n-pentyl bromide
DMF, rt, 16 h

\[
53 \quad + \quad 54
\]

\(^1\text{H NMR (300 MHz, CDCl₃)}\)

[Image of an NMR spectrum]
Table 4, Entry 3 (Conditions A)

\[
\text{O}_2\text{N} \quad \text{N} \\
\text{H} \\
\text{N} \\
\text{H} \\
\text{O}_2\text{N}
\]

1.1 equiv. NaH, 1.2 equiv. n-pentyl bromide
THF, N₂, 0 °C → 50 °C, 24 h

\[
\begin{align*}
55 & \quad + \quad 56
\end{align*}
\]

\(^1\text{H NMR (300 MHz, CDCl}_3\)
Table 4, Entry 3 (Conditions B)

\[
\begin{array}{c}
\text{1.5 equiv. Cs₂CO₃,} \\
\text{1.2 equiv. n-pentyl bromide} \\
\text{DMF, rt, 16 h}
\end{array}
\]

\[
\begin{array}{c}
\text{55} \\
\text{56}
\end{array}
\]

\(^1\text{H NMR (300 MHz, CDCl₃)}\)
Table 4, Entry 4 (Conditions A)

1H NMR (300 MHz, CDCl₃)
Table 4, Entry 4 (Conditions B)

\[ \text{1.5 equiv. Cs}_2\text{CO}_3, \]
\[ \text{1.2 equiv. } n\text{-pentyl bromide} \]
\[ \text{DMF, rt, 16 h} \]

\[ \text{57} + \text{58} \]

\[ ^1\text{H NMR (300 MHz, CDCl}_3\text{)} \]
Table 4, Entry 5 (Conditions A)

1H NMR (300 MHz, CDCl3)
Table 4, Entry 5 (Conditions B)

\[
\begin{align*}
\text{1.5 equiv. Cs}_2\text{CO}_3, \\
\text{1.2 equiv. } n\text{-pentyl bromide} \\
\text{DMF, rt, 16 h}
\end{align*}
\]

\[\text{59} + \text{60}\]

\(^1\text{H NMR (300 MHz, CDCl}_3\)
Table 4, Entry 6 (Conditions A)

\[
\text{1.1 equiv. NaH, 1.2 equiv. } n\text{-pentyl bromide} \quad \text{THF, N}_2, 0 \degree C \rightarrow 50 \degree C, 24 \text{ h}
\]

61 \quad + \quad 62

\[\text{\^{1}H NMR (300 MHz, CDCl}_3\text{)}\]
Table 4, Entry 6 (Conditions B)

\[
\text{O} \quad \text{O} \\
\text{N} \quad \text{N} \\
\text{H} \\
\text{H} \\
\text{N} \\
\text{N} \\
\text{O} \quad \text{O} \\
\]

\[
\text{1.5 equiv. Cs}_2\text{CO}_3, \\
\text{1.2 equiv. } n\text{-pentyl bromide} \\
\text{DMF, r.t, 16 h} \\
\]

\[
\text{61} + \text{62} \\
\]

\[\text{^1H NMR (300 MHz, CDCl}_3\text{)}\]
Table 4, Entry 7 (Conditions A)

\[ \text{1.1 equiv. NaH, 1.2 equiv. } n\text{-pentyl bromide} \]
\[ \text{THF, } N_2, 0 \degree C \rightarrow 50 \degree C, 24 \text{ h} \]

\[ \text{63} \quad \text{64} \]

\(^1\text{H NMR (300 MHz, CDCl}_3\))
Table 4, Entry 7 (Conditions B)

\[ \text{NMR (300 MHz, CDCl}_3\text{)} \]

$^1$H NMR (300 MHz, CDCl$_3$)
Table 5, Entry 1

1.1 equiv. NaH,
1.1 equiv. 15-crown-5,
1.2 equiv. n-pentyl bromide
THF, N₂, 0 °C → 50 °C, 24 h

1H NMR (300 MHz, CDCl₃)
Table 5, Entry 2

1.1 equiv. NaH, 5.5 equiv. 15-crown-5, 1.2 equiv. n-pentyl bromide
THF, N₂, 0 °C → 50 °C, 24 h

1H NMR (300 MHz, CDCl₃)
Table 6, Entry 1 (Conditions A)

\[
\text{1.1 equiv. NaH, 1.2 equiv. n-pentyl tosylate} \\
\text{THF, N}_2, 0 \, ^\circ\text{C} \to 50 \, ^\circ\text{C, 24 h}
\]

\[
\begin{align*}
\text{9} & \quad \text{10} \\
\text{11}
\end{align*}
\]

$^1$H NMR (400 MHz, CDCl$_3$)
Table 6, Entry 1 (Conditions B)

\[
\begin{align*}
\text{O} & \quad 1.5 \text{ equiv. } \text{Cs}_2\text{CO}_3, \\
\text{N} & \quad 1.2 \text{ equiv. } n\text{-pentyl tosylate} \\
\text{DMF, rt, 16 h} & \quad 10 \\
& \quad 11
\end{align*}
\]

\[\text{H NMR (400 MHz, CDCl}_3\text{)}\]

\[\text{NMR Spectrum}\]
Table 6, Entry 2 (Conditions A)

\[
\begin{align*}
\text{9} & \xrightarrow{1.1 \text{ equiv. NaH,}} \text{1.2 equiv. benzyl bromide} \\
& \xrightarrow{\text{THF, N}_2, 0 \degree \text{C} \rightarrow 50 \degree \text{C}, 24 \text{ h}} \\
& + \text{69} + \text{70}
\end{align*}
\]

\[\text{\textsuperscript{1}H NMR (400 MHz, CDCl}_3\text{)}\]
Table 6, Entry 2 (Conditions B)

\[
\begin{align*}
\text{9} & \xrightarrow{\text{1.5 equiv. } \text{Cs}_2\text{CO}_3, \\
& \text{1.2 equiv. benzyl bromide}} \text{DMF, } \tau, 16 \text{ h} \\
& \text{69} + \text{70}
\end{align*}
\]

\(^1\)H NMR (400 MHz, CDCl\(_3\))
Table 6, Entry 3 (Conditions A)

\[ \text{9} \xrightarrow{1.1 \text{ equiv. NaH,} \ 1.2 \text{ equiv. benzyl tosylate}} \text{69} + \text{70} \]

\[ \text{THF, N}_2, \ 0 \ ^\circ \text{C} \rightarrow 50 \ ^\circ \text{C,} \ 24 \ \text{h} \]

$^1$H NMR (400 MHz, CDCl$_3$)
Table 6, Entry 3 (Conditions B)

\[ \text{1H NMR (400 MHz, CDCl}_3) \]
Table 6, Entry 4 (Conditions A)

1.1 equiv. NaH,
1.2 equiv.

1H NMR (300 MHz, CDCl₃)
Table 6, Entry 4 (Conditions B)

\[
\begin{align*}
\text{1.5 equiv. } Cs_2CO_3, \\
\text{1.2 equiv. } Br \\
\text{DMF, rt, 16 h}
\end{align*}
\]

\[
\begin{align*}
9 & \xrightarrow{\text{Br}} 71 + 72
\end{align*}
\]

\[\text{^1H NMR (400 MHz, CDCl}_3\text{)}\]
Table 6, Entry 5 (Conditions A)

1.1 equiv. NaH, 1.2 equiv. Br
THF, N₂, 0 °C → 50 °C, 24 h

1H NMR (300 MHz, CDCl₃)
Table 6, Entry 5 (Conditions B)

1.5 equiv. Cs₂CO₃,
1.2 equiv.

DMF, rt, 16 h

9 → 73 + 74

¹H NMR (400 MHz, CDCl₃)
Table 6, Entry 6 (Conditions A)

\[ \text{TsO} \xrightarrow{\text{THF, N}_2, 0 \degree C \to 50 \degree C, 24 \text{ h}} \text{73} + \text{74} \]

\[ \text{H NMR (300 MHz, CDCl}_3 \text{)} \]

\[ ^1H \text{ NMR (300 MHz, CDCl}_3 \text{)} \]
Table 6, Entry 6 (Conditions B)

1.5 equiv. Cs₂CO₃,
1.2 equiv.

\[
\text{TsO} \xrightarrow{\text{DMF, } \tau, 16 \text{ h}} \begin{align*}
\text{Product 73} \\
\text{Product 74}
\end{align*}
\]

\(^1\text{H NMR (400 MHz, CDCl₃)}\)
Table 6, Entry 7 (Conditions A)

\[ 1.1 \text{ equiv. NaH,} \]
\[ 1.2 \text{ equiv.} \]
\[ \text{THF, } N_2, 0 \, ^\circ C \rightarrow 50 \, ^\circ C, 24 \, h \]

\[ 9 \rightarrow 75 + 76 \]

\[ ^1H \text{ NMR (300 MHz, CDCl}_3) \]

\[ \text{ppm} \]

S199
Table 6, Entry 7 (Conditions B)

1.5 equiv. Cs$_2$CO$_3$, 1.2 equiv. Br

DMF, rt, 16 h

1H NMR (400 MHz, CDCl$_3$)
Table 6, Entry 8 (Conditions A)

\[
\begin{align*}
\text{1.1 equiv. NaH,} \\
\text{1.2 equiv.} \\
\text{TsO} & \quad \text{THF, N}_2, \text{ 0 °C} \rightarrow 50 \text{ °C,} \\
\text{24 h} & \\
\end{align*}
\]

\[
\begin{align*}
9 & \quad \rightarrow \\
& \quad 75 + 76
\end{align*}
\]

\[^1\text{H NMR (300 MHz, CDCl}_3\)]
Table 6, Entry 8 (Conditions B)

\[
\text{1.5 equiv. } \text{Cs}_2\text{CO}_3, \\
\text{1.2 equiv.} \\
\text{TsO} \quad \text{DMF, rt, 16 h} \\
\text{9} \quad \text{75} \quad + \quad \text{76}
\]

\(^1\text{H NMR (300 MHz, CDCl}_3\text{)}\)
Table 6, Entry 9 (Conditions A)

\[
\begin{align*}
\text{1.1 equiv. NaH,} \\
\text{1.2 equiv.} \\
\text{THF, N}_2, 0 \degree \text{C} \rightarrow 50 \degree \text{C,} \\
\text{24 h}
\end{align*}
\]

\[
\begin{align*}
\text{9} & \xrightarrow{\text{Br} \text{H}} \text{77} + \text{78}
\end{align*}
\]

$^1$H NMR (300 MHz, CDCl$_3$)
Table 6, Entry 9 (Conditions B)

\[ \text{1.5 equiv. } \text{Cs}_2\text{CO}_3, \]
\[ \text{1.2 equiv. } \]
\[ \text{DMF, rt, 16 h} \]

\[ \begin{array}{c}
\text{9} \\
\text{77} \\
\text{78}
\end{array} \]

\[^1\text{H NMR (400 MHz, CDCl}_3\text{)}\]
References

1. Ferrari, M.; Ripa, A.; Ripa, G.; Sisti, M. J. Heterocycl. Chem. 1989, 26, 531–532. DOI: 10.1002/jhet.5570260251
2. Tang, M.; Kong, Y.; Chu, B.; Feng, D. Adv. Synth. Catal. 2016, 358, 926 – 939. DOI: 10.1002/adsc.201500953
3. Banister, S.D.; Moir, M.; Stuart, J.; Kevin, R.C.; Wood, K.E.; Longworth, M.; Wilkinson, S.M.; Beinat, C.; Buchanan, A.S.; Glass, M.; Connor, M.; McGregor, I.S.; Kassiou, M. ACS Chem. Neurosci. 2015, 6, 1546–1559. DOI: 10.1021/acscchemneuro.5b00112
4. Alaime, T.; Daniel, M.; Hiebel, M.-A.; Pasquinet, E.; Suzenet, F.; Guillaumet, G. Chem. Commun. 2018, 54, 8411–8414. DOI: 10.1039/C8CC03612H
5. Bartsch R.A.; Yang I-W. J. Het. Chem. 1984, 21, 1063–1064. DOI: 10.1002/jhet.5570210428
6. Bamberger, E.; Goldberger, A.V. Justus Liebig’s Ann. Chem. 1899, 305, 339–362. DOI: 10.1002/jlac.18993050306
7. Li, P.; Zhao, J.; Wu, C.; Larock, R.C.; Shi, F. Org. Lett. 2011, 13, 3340–3343. DOI: 10.1021/ol201086g
8. Chen, G.; Hu, M.; Peng, Y. J. Org. Chem. 2018, 83, 1591–1597. DOI: 10.1021/acs.joc.7b02857
9. Song, P.; Chen, M.; Ma, X.; Liu, T.; Zhou, Y.; Hu, Y. Bioorg. Med. Chem. 2015, 23, 1858–1868. DOI: 10.1016/j.bmc.2015.02.004
10. Tang, R-J.; Milcent, T.; Crousse, B. J. Org. Chem. 2018, 83, 930–938. DOI: 10.1021/acs.joc.7b02920
11. Chevalier, A.; Ouahrouch, A.; Arnaud, A.; Gallavardin, T.; Franck, X. RSC Adv. 2018, 8, 13121–13128. DOI: 10.1039/C8RA01546E
12. Longworth, M.; Banister, S.D.; Mack, J.B.C.; Glass, M.; Connor, M.; Kassiou, M. Forensic Toxicol. 2016, 34, 286–303. DOI: 10.1007/s11419-016-0316-y
13. Palit, S.; Bera, S.; Singh, M.; Mondal, D. Synthesis, 2015, 47, 3371–3384. DOI: 10.1055/s-0034-1381135
14. Palmieri, A.; Gabrielli, S.; Ballini, R. Chem. Commun. 2010, 46, 6165–6167. DOI: 10.1039/C0CC01097A
15. Kazemi, F.; Massah, A.R.; Javaherian, M. Tetrahedron, 2007, 63, 5083–5087. DOI: 10.1016/j.tet.2007.03.083
16. Maskill, H. J. Chem. Soc., Perkin Trans. 2, 1986, 1241–1246. DOI: 10.1039/P29860001241
17. Weweler, J.; Younas, S.L.; Streuff, J. Angew. Chem., Int. Ed. 2019, 58, 17700–17703.
DOI: 10.1002/anie.201908372
18. Deruer, E.; Hamel, V.; Blais, S.; Canesi, S. Beilstein J. Org. Chem. 2018, 14, 1203–1207. DOI: 10.3762/bjoc.14.101